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Abstract  
Background: According to the United Kingdom prospective diabetes study, 
metformin is considered the drug of choice in overweight newly diagnosed type 2 
diabetic patients. Metformin is well characterized as a substrate of the organic 
cation transporter (OCT) 1 and OCT 2. In vitro and in vivo studies have revealed 
that OCT1 and OCT2 genes exhibited polymorphic variations in different ethnic 
groups, and metformin uptake was impaired in individuals who carried 
polymorphic single nucleotide polymorphisms (SNPs). It was observed that in 
clinical practice there was inter-individual variation to metformin therapy; it could 
be due to a variety of reasons including genetic variations of the OCT1 and OCT2 
genes. To date no genetic studies have been conducted on Arab populations to 
investigate the clinical effects of genetic polymorphisms of OCT1 and OCT2 
genes on metformin plasma concentrations in diabetic populations. 
Objective: To investigate factors affecting metformin plasma concentrations and 
to analyse genetic variations of OCT1, OCT2, and serine threonine kinase (LKB1) 
genes in the United Arab Emirates (UAE) population. Also, to investigate the 
possible effects of genetic variations of these genes on metformin plasma 
concentrations among a diabetic group of patients in the UAE population. 
Study design: A cross sectional prospective study recruited control non-diabetic 
and diabetic (test) individuals from four different hospitals and health centres in 
the UAE. Diabetic patients had been prescribed metformin therapy for at least 
seven days. One fasting blood sample was taken to investigate metformin plasma 
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concentrations, fasting plasma glucose, glycated haemoglobin, serum creatinine, 
and DNA genotypes. 
Results: Overall, 170 control non-diabetic and 292 diabetic subjects completed the 
study. The mean age for the diabetic patients was 54± 0.7 years, mean glomerular 
filtration rate (GFR) was 88 ±1.6 mL/min/1.73m2 , mean metformin dose was 1622 
±28 mg/day, and the mean metformin plasma concentration was 0.62 ±0.03 mg/L. 
Among the reported OCT1 SNPs in the database 12 were polymorphic in the UAE 
population, while five polymorphisms were reported in the OCT2 gene, and two 
were polymorphic in the LKB1 gene. One novel synonymous Ser 279 (A/G) SNP 
was found in exon 1 in the OCT2 gene that has not been reported in any other 
population with minor allele frequency (MAF) of 1.03%.  
The result of the current study showed that among the investigated variables, 
metformin dose, GFR, OCT1-E1 synonymous SNP rs1867351 and OCT1-E9 non-
synonymous 488Arg>Met SNP were found to be associated with metformin 
plasma concentrations with p = 0.002, p = 0.008, p = 0.005, and p = 0.007 
respectively.      
Conclusion: This is the first large study to investigate the allele frequencies of 
OCT1, OCT2, and LKB1 genes in the Eastern Mediterranean population, and to 
report the effect of genetic variations of drug transporters on metformin plasma 
concentrations. These findings emphasise that each ethnic group carries a unique 
genetic background that should be genotyped and investigated independently. It 
also highlights the important role played by the synonymous SNPs on the drug 
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transporters function. In order to implement these findings in clinical practice, 
further pharmacoeconomic studies are recommended to evaluate the cost 
effectiveness of genotyping selected sub-groups of patients for genetic variations 
in OCT genes. It is also recommended that further pharmacogenomic studies 
should be carried out to investigate the impact of genetic variations in other 
candidate genes that might affect metformin efficacy and disposition, such as 
plasma membrane monoamine transporter (PMAT) and multidrug and toxic 
extrusion (MATE) genes.   
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1 Background   
Diabetes is one of the most common non-communicable diseases worldwide and is 
a leading cause of death in many countries; the global epidemic of diabetes will 
impact on both the developed and the developing world (1-3). An estimated 336 
million people worldwide are expected to have diabetes by the year 2030, of which 
1,673,000 in Australia and 684,000 in the United Arab Emirates (UAE) (4). The 
prevalence of diabetes is increasing due to population growth, ageing, 
urbanization, and increasing levels of obesity and physical inactivity (5-7). It is of 
note that the rising incidence of obesity may cause these figures to be an 
underestimate of future diabetes prevalence.   
Diabetes mellitus (DM) is a public health issue of significant economic importance 
because of the chronic nature of the disease, its high and globally increasing 
prevalence (4, 8-9), the demand for multi-modal treatment (10-11), and the serious 
complications associated with long disease duration (12-14).  
According to the guidelines, metformin is considered the first choice of mono-
therapy in patients with type 2 DM (8, 15-16), and it can be safely combined with 
other classes of oral hypoglycaemic agents (11). However, a total of 38% of type 2 
diabetes patients receiving metformin therapy failed to reach the target glycated 
haemoglobin (HbA1c) level (15, 17). Metformin is well characterized as a 
substrate of the organic cation transporter (OCT)1 and OCT2 genes (18-20). 
Genetic polymorphisms in the drug transporters gene contribute to variability in 
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the pharmacokinetic properties of metformin (21-23). Genetic and molecular 
studies have demonstrated that OCT genes exhibit polymorphic variation in the 
coding region (24-27) and in order to investigate the pattern of polymorphisms that 
exist in OCT1 and OCT2 genes, various studies have screened for genetic variants 
of these genes in different populations, including Caucasian (27), Japanese (28) 
and Korean (29). A number of polymorphisms were found in the studied 
populations, and subsequent functional analysis of the reported variations showed 
reduced activities of those variants towards their substrates (24-25, 30-31). Nearly 
all of the studies were conducted on healthy individuals (24-26, 29, 32), and to our 
knowledge only one employed diabetic subjects utilizing a small sample size (21). 
Furthermore, no study has occurred in the Arab population. Thus, in order to 
investigate genetic polymorphisms and their role in clinical pharmacokinetics, 
therapeutic effects and safety a large scale prospective study in patients with 
diabetes is required which should include different ethnic groups from different 
genetic backgrounds.   
1.1  Prevalence of diabetes 
The worldwide prevalence of diagnosed diabetes has increased dramatically over 
the past 40 years. In 1985, there were approximately 30 million people with 
diabetes worldwide (8),  by 1995, this number had escalated to 135 million (8), 
and by 2030, it is projected that the incidence of diabetes will increase by 40%, 
affecting 336 million people (4). The published age and sex specific estimations of 
current and future diabetes prevalence have shown differences in numbers; 
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however, the dramatic escalating prevalence of diabetes was not debated amongst 
all of the studies.  
Epidemiological studies have revealed that the age structure of the diabetic 
populations of developed and developing countries were noticeably different. The 
majority of the cases diagnosed in the developed countries were in the oldest age 
group ≥60 years (4-5, 9). In contrast, the majority of people with diabetes in 
developing countries were in the 45 to 64 year old age group (4-5, 9). Thus the 
economic productivity, fertility, and reproduction of these communities especially 
in developing countries would be significantly affected. Figure 1 shows diabetes 
cases in 2000 and projections for 2030 (33). 
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Figure 1: Millions of cases of diabetes in 2000 and projections for 2030, with projected 
percent changes   
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1.2 Economic burden of diabetes mellitus 
People with diabetes are more likely to use health services than people without 
diabetes (9, 34), and to use them more often and for longer periods of time (35-37). 
Most of the global epidemiological data utilized the prevalence of DM as the basis 
for projections of economic impact of the disease (9, 34, 38). To assess the 
economic impact of its prevalence, most of the economic studies have used direct, 
indirect, and intangible cost approaches (9, 34, 38). The direct costs of the disease 
are those associated with hospitalization, ambulatory care, and medication. The 
indirect costs represent lost productivity due to morbidity and, possibly, premature 
mortality. Finally, the intangible costs are those to which it is difficult to attach a 
monetary value, such as reduced life expectancy and quality of life (39-41).   
According to American Diabetes Association (ADA) (36) diabetes cost the United 
States (US) an estimated $132 billion in 2002 in medical expenditure and lost 
productivity. This estimation was 74% higher than 1997 (6). This estimated cost  
underestimates the true burden of diabetes, because it omits intangibles, such as 
pain and suffering, care provided by non-paid caregivers, and several areas of 
health care spending where people with diabetes probably use services at higher 
rates than people without diabetes; such as dental care, optometry care, podiatric 
visits, and the use of licensed dieticians. Moreover, this cost estimation excluded 
undiagnosed cases of diabetes. Worldwide, the direct cost of diabetes increased 
from 1.7 billion US dollars in 1969 to 4.4 billion US dollars in 1997 (38). In 
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Australia, direct health care expenditure on diabetes was estimated to be 784 
million Australian dollars in 2000-01 (42).  
1.3 Classifications and pathophysiology of DM 
DM is a metabolic disorder of multiple aetiology characterized by chronic 
hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism 
resulting from defects in insulin secretion, insulin action, or both (43-44).  
The new classification system identifies four types of DM: type 1, type 2, "other 
specific types" and gestational diabetes (45).  
The alterations of metabolism in patients with type 2 diabetes partially overlap 
with those alterations of metabolism seen in patients with type 1 diabetes. 
Absolute or relative deficiency of insulin is common to both disorders, as is a 
severe disturbance of the patterns of glucose and lipid levels in plasma (46). 
However, the fluctuations of plasma glucose are less extreme in type 2 diabetes 
than in type 1 diabetes, and the exaggerated catabolic state of severe insulin 
deficiency often seen in type 1 is uncommon in type 2 (46-47). The 
pharmacological therapy is limited in type 1 DM to insulin dependency. This study 
will focus entirely in type 2 DM. Therefore any further discussions in the 
following sections relate only to type 2 DM. 
The pathophysiology of type 2 DM is characterized by three abnormalities: 
impaired insulin secretion, peripheral insulin resistance, and excessive hepatic 
glucose production (43-44, 48). Obesity, particularly visceral or central (as 
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evidenced by the hip-waist ratio), is very common in type 2 DM (49). In the early 
stages of the disorder glucose tolerance remains normal despite insulin resistance, 
because the pancreatic beta cells compensate by increasing insulin output (50-51). 
As insulin resistance and compensatory hyperinsulinemia progress the pancreatic 
islets in certain individuals are unable to sustain the hyperinsulinemic state. 
Impaired glucose tolerance (IGT), characterized by elevation in postprandial 
glucose, then develops (43-44). A further decline in insulin secretion and an 
increase in hepatic glucose production lead to overt diabetes with fasting 
hyperglycemia. Ultimately, beta cell failure may ensue. 
1.4 Prevention of diabetes 
The escalating prevalence of DM with its high morbidity and excess mortality is 
imposing a worldwide burden on healthcare systems (9, 34, 38). Effort and 
attention needs to be given to prevention programs that will help greatly in 
reducing the costs of health expenditure on diabetes and its complications and 
burden to governments, public and private companies, and individuals.  
The Finnish Diabetes Prevention Study (DPS)(52) was one of the first large 
controlled, randomized study to show that in a high risk population, lifestyle 
intervention was associated with a 58% decrease in the risk of progression of type 
2 DM (p< 0.001). Similar observations were reported in the American Diabetes 
Prevention Program (DPP)(53). However DPP randomized subjects to intensive 
lifestyle intervention and standard lifestyle intervention plus metformin 850 mg 
twice daily. The DPP study revealed that treatment with metformin and 
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modification of lifestyle were two highly effective means of delaying or 
preventing type 2 DM with a 31% and 58%  reduction of diabetes risk, 
respectively. This study showed for the first time that metformin could be used in 
the prevention of type 2 diabetes especially with individuals who fail to comply 
with intensive lifestyle intervention.  
1.5  Prediction of diabetes 
1.5.1  Metabolic syndrome  
The clinical importance of metabolic syndrome (MetS) is related to its putative 
impact on cardiovascular morbidity and mortality and it’s possibility of predicting 
type 2 DM. Diabetes by itself is considered to be a risk factor for cardiovascular 
disease (CVD), thus increased CVD risk occurs for individuals suffering from both 
DM and MetS (54) (55) (56) .  
MetS has received increased attention in the past few years. It is a constellation 
and clustering of interrelated risk factors of metabolic abnormalities including 
glucose intolerance (type 2 DM, IGT, or impaired fasting glycaemia [IFG]), 
insulin resistance, central obesity, dyslipidaemia, and hypertension, which appear 
to directly promote the development of atherosclerotic cardiovascular disease (54-
60). In an effort to gain recognition of its existence, several organizations have 
attempted to formulate and develop an internationally recognized definition of the 
MetS (Table 1).  
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All of the above definitions are sex-specific, with different thresholds for both 
waist circumference and high density lipoprotein (HDL) cholesterol between 
males and females.  
Many studies compared the prevalence of MetS using different criteria. Most of 
the published studies reported the prevalence of MetS based on WHO and NCEP 
ATPIII definitions. Despite of the differences in the study designs, sample 
selection, year that they were undertaken, precise definition of the MetS used, and 
age and sex structure of the population of the studies, most of them came out with 
a consistent finding that the prevalence of the syndrome is highly age-dependent. 
This pattern was clear in the study conducted in the USA where the prevalence 
increased from 7% in participants aged 20-29 years to 44% and 42% for those 
aged 60-69 years and at least 70 years, respectively (61).  Similar finding was 
observed in Greece studies (62-63), the Botania study in Finland and Sweden (54), 
and in Cameron et al. study (64) who published a detailed review about the 
worldwide  prevalence of the syndrome with different criteria. 
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Table 1: Comparison of definitions of the metabolic syndrome 
WhO (1998) (65) NCEP ATPIII (2001) (57) NHLBI/AHA (2005) (66) IDF (2005) (67) 
Diabetes or IFG or IGT or insulin 
resistance (hyperinsulaenemic, 
euglycaemic clam-glucose uptake in 
lowest 25%) plus two or more of the 
following 
Three or more of the following Three or more of the following Central obesity- waist circumference- 
ethnicity specific 
Obesity/central 
obesity 
 
 
   
Body mass index 
(BMI) 
>30    
Waist-to-hip ratio >0.9 (men) or >0.85 
(female) 
   
Waist 
circumference 
Men 
 >102 cm >102 cm ≥94 cm 
Women  >88 cm >88 cm ≥80 cm 
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Hypertension BP>140/90 mm Hg BP≥135/85 mm Hg BP≥135/85 mm Hg or specific 
medication 
BP≥135/85 mm Hg or specific 
medication 
Triglycerides ≥1.7 mmol/L (≥150 
mg/dl) 
≥1.7 mmol/L (≥150 mg/dl) ≥1.7 mmol/L (≥150 mg/dL) or 
specific medication 
≥1.7 mmol/L (≥150 mg/dL) or 
specific medication 
HDL-cholesterol 
men 
<0.9 mmol/L <1.03 mmol/L (40 mg/dl) <1.03 mmol/L (40 mg/dL) or 
specific medication 
<1.03 mmol/L (40 mg/dL) or specific 
medication 
Women <1.0 mmol/L <1.29 mmol/L (<50 mg/dL) <1.29 mmol/L (<50 mg/dL) or 
specific medication 
<1.29 mmol/L (<50 mg/dL) or 
specific medication 
Fasting plasma 
glucose (FPG) 
 ≥6.1 mmol/L (≥110 mg/dL) ≥5.6 mmol/L (≥100 mg/dL) ≥5.6 mmol/L (≥100 mg/dL) 
Microalbuminuria Albumin excretion 
>20 μg/min 
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1.6 Complications of diabetes 
Diabetes is an important and independent risk factor for the development of 
atherothrombosis and related cardiovascular events (68-70). It is characterized by 
specific changes in microvessels, thus causing diabetic microangiopathy, namely 
nephropathy, retinopathy, and neuropathy. (71-74)   
Diabetes noticeably reduces life span; many observational studies have shown that 
CVD is a major factor in reducing longevity in persons with diabetes (7, 70-71, 75). 
About 80% of all diabetic patients die from CVD (7, 70, 74-76), 75% of such 
deaths are due to coronary heart disease (CHD), and the remaining 25% to 
cerebrovascular, peripheral or other macrovascular diseases (69-70).  
The beneficial effects of improved glycemic control on microvascular 
complications, including retinopathy, nephropathy, and neuropathy, have been 
documented in several randomized studies published during the last 20 years. In 
order to document the effect of improved glycemic control on reduction of 
macrovascular complications a meta-analysis study was performed by pooling data 
from several randomized trials (77). Ten studies that included 14 randomized 
comparisons of intensified and conventional treatment were included. The result 
showed that improved glycemic control (measured by HbA1c %) translated into 
substantial reductions in macrovascular risk in type 2 DM (combined incidence rate 
ratios was 0.81). Moreover, they found that in type 2 DM, substantial effects were 
observed for peripheral vascular disease (PVD) and stroke, whereas cardiac events 
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were not found to be reduced significantly. This finding could be explained by the 
fact that the metabolic abnormalities typical for type 2 DM not only lead to insulin 
resistance and hyperglycemia but also to dyslipidemia, arterial hypertension, 
endothelial dysfunction, and increased platelet hyperactivity and coagulability (68-
69, 78-80). Improving blood glucose control without also addressing the other 
abnormalities, most importantly hypertension, dyslipidemia, and platelet 
hyperactivity, may therefore produce only limited benefit (71, 77).  
Recent findings from the US (61, 81) and the United Kingdom (UK) (82) have 
shown an unfavourable trend in CVD mortality in younger people (35-44 years). In 
this age group (in woman from the US and men from the UK), CVD mortality 
increased significantly for the first time over two decades (p< 0.0001) (61, 81-82). 
These adverse outcomes were considered to be related to the recent epidemic of 
MetS and DM (61, 81).  
As the nature of the syndrome being a cluster of multiple diseases, the management 
also requires multiple interventions targeting individual risk factors. Education 
about MetS is an essential element in the management plan and it should involve 
both physicians and patients. The overall assessment should weigh the risk and 
benefit of non-pharmacological and pharmacological interventions that 
significantly improve CVD risk factors among patients.     
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1.7 Management of type 2 DM 
Weight control and long term management of obesity are central to the prevention 
of diabetes and the optimal management of people with diabetes. Accordingly, 
lifestyle interventions, irrespective of the concomitant use of pharmacologic anti-
diabetic therapy, remains the cornerstone of the management of type 2 DM (83-84).  
Treatment goals for patients with type 2 DM specify targets for glycemic and other 
cardiovascular risk factors (78, 83-85). For most patients, lifestyle intervention will 
be tried first, although commencement of pharmacological treatment may be 
necessary in patients with poor glycemic control and low body weight (10, 85). The 
long term efficacy of lifestyle intervention is often poor. For example, diet based 
therapy in the United Kingdome Prospective Diabetes Study (UKPDS) controlled 
HbA1c to <7.0% in only 25% of patients after 3 years, 11% after 6 years and 9% 
after 9 years of treatment (15).  
Pharmacological management of type 2 DM includes insulin therapy and oral 
hypoglycaemic therapy. To date, seven types of medications are commonly used to 
treat type 2 DM; insulin, metformin, sulphonylureas, thiazolidinediones, 
meglitinides, dipeptidyl peptidase-4 inhibitors, and alpha glucosidase inhibitors. 
According to the UKPDS (15) intensive treatment with metformin reduced stroke, 
diabetes related end points, and all cause mortality when used as mono-therapy in 
overweight, newly diagnosed type 2 diabetic individuals, compared with intensive 
treatment with insulin or sulphonylureas, despite similar glycemic control (15, 71). 
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Consequently, metformin is regarded as the drug of choice for the treatment of 
overweight newly diagnosed type 2 diabetic subjects.  
1.8 Metformin 
 Metformin is a biguanide (1, 1-dimethylbiguanide)(Figure 2) used as an oral 
hypoglycemic agent in the treatment of type 2 DM (86). It is the only biguanide 
available in the market, and is marketed as Glucophage®, Diaformin®, 
Glucomet®, and Diabex® (87-88).  It is used as mono-therapy or in combination 
with other types of oral antidiabetic agents or insulin (86, 89-90).  
 
 
Figure 2: Metformin chemical structure 
 
1.9 Combining metformin with other hypoglycaemic agents 
Metformin is considered the first choice of mono-therapy in patients with type 2 
DM (8, 15-16). However, some patients fail to achieve target HbA1c level with 
metformin mono-therapy (15, 17). Treatment options for metformin mono-therapy 
failure include the addition of other available hypoglycemic agents. The efficacy of 
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different hypoglycemic drugs in combination with metformin was investigated in 
several randomized controlled trials. Overall, sulphonylureas (91-94), alpha 
glucosidase inhibitors (95-97), thiazolidinedione (98-99), and glitinide (11, 100-
101) were all effective and tolerable as add on therapy to metformin. However, 
sulphonylureas, alpha glucosidase inhibitors, and glinides, seems to have similar 
efficacy when used as add on therapy in patients with type 2 diabetes inadequately 
controlled with metformin mono-therapy. Thiazolidinediones often have lower 
effects on HbA1c in the first six months, although their efficacy could be equal to 
or higher than other agents in the long term (98-99). The limited number of 
randomized trials available does not allow any definitive conclusion regarding the 
efficacy of different agents in patients failing metformin mono-therapy (11). Some 
factors, including initial HbA1c or duration of diabetes, dietary, and physical 
activity could affect the extent of the reduction of HbA1c in individual studies. 
Thus in clinical practice, the choice of drugs to be added to metformin mono-
therapy is mainly individualized and sometimes subjected to the clinician’s 
preference and the guidelines they follow. For example, the Australian guidelines 
(102) recommend sulphonylureas as the first add on medication to metformin 
therapy where patients fail to achieve the target HbA1c level with metformin mono-
therapy. However, it does not clearly specify the next add on medication in case of 
failure with both metformin and sulphonylureas; it is left to physician’s preference 
and judgment.  
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1.10  Metformin pharmacokinetic properties 
The pharmacokinetic properties of metformin have been investigated in patients 
with diabetes (103-104), in healthy volunteers (104-106), and in diabetic patients 
with impaired renal function (107), using the oral and intravenous routes of 
administration. The pharmacokinetic properties of metformin have been well 
characterized in different populations (104-106, 108-111) and no significant 
difference was observed in the metformin pharmacokinetic parameters among those 
populations.   
Compartmental analysis has indicated that metformin pharmacokinetics is best 
described by a two compartment open model (103, 112). Elimination from the 
central compartment is relatively rapid (t1/2 α ≈ 2 ho u rs), with  slower elimination 
from the deep compartment (t1/2 β≈ 12 to 14 hours), involving only small fraction 
(<5%) of the administered dose (113). Erythrocyte was suggested as a marker for a 
deep compartment to measure metformin distribution and potential accumulation in 
chronic metformin therapy (114-115).  
1.10.1 Absorption 
Gastrointestinal absorption of metformin is incomplete with 20 to 30% of an oral 
dose being recovered in the faeces (103, 105-106). Metformin is slowly absorbed 
from the proximal small intestine and mainly excreted from urine without 
undergoing liver metabolism (105-106, 113). Because the rate of metformin 
absorption is slower than its rate of elimination , intestinal absorption is the rate 
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limiting step of metformin disposition (106, 113), thus making the absorption of 
metformin  incomplete and dose-dependent (104, 106, 113).    
Metformin doses of 500 mg to 1500 mg have an absolute bioavailability of 50% to 
60%, and decreases with increased dose (105-106). It was observed that metformin 
bioavailability decreased from 86% with 250 mg of metformin HCl to 42% with 
2000 mg, and the 1500 mg dose had lower bioavailability than the 500 mg 
metformin dose (104-106, 108, 116). These observations show that the absorption 
of metformin is dose dependent and is subject to a saturable active transport process 
(104, 116). Food slightly reduced the rate and extent of metformin absorption with 
a 20% lower area under the plasma concentration-time curve (AUC) value and 35% 
lower maximum concentration (Cmax) value (103, 112). 
1.10.2 Distribution 
Metformin is rapidly distributed however, a slow transfer to a deep compartment 
also seemed to occur (103, 105-106). Metformin accumulated in the esophagus, 
stomach, duodenum, salivary glands and kidneys (105, 112). Protein binding is 
negligible. Following a single oral doses, the mean apparent volume of distribution 
(Vd) of metformin ranged from 63 to 276 L (105-107, 112, 117).  
1.10.3 Metabolism 
Metformin does not undergo metabolism, but is excreted largely in the unchanged 
form (103, 105-106). It is a strong base (pKa 11.5) hence the drug is protonated at 
physiologic pH (118-119).  
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1.10.4 Excretion 
Metformin undergoes rapid renal excretion through active secretion. It has a plasma 
elimination half life (t1/2 β) ranging from 1.5 to 4.5 hours after intravenous 
injection, and from 2.0 to 6.0 hours after oral administration in healthy volunteers 
(105-107). 
1.11  Plasma concentrations and therapeutic efficacy 
Metformin plasma levels are not usually monitored in order to determine the 
effectiveness of the treatment, and it has little clinical value except when lactic 
acidosis is present (103). The normal therapeutic level of metformin is not defined; 
however some studies have investigated the relationship between metformin levels 
and clinical outcome in patients with type 2 DM. A therapeutic range of 0.6 ±0.5 
mg/L in the fasting state had been suggested by Lalau et al. (120) . In this study  
patients with type 2 DM (n= 58) were assumed to have achieved the therapeutic 
range for metformin because they had been receiving well-tolerated chronic 
metformin therapy at the recommended dosage of 1,700 to 2550 mg/day and were 
well controlled at the time the study was conducted. Their arterial lactate levels 
were significantly low (1.09 ±0.06 mmol/L). However, the study did not give 
details of the glucose and HbA1c levels or the mean duration in which their 
glycemic control was stable. Other studies have also suggested the same 
concentration range of metformin at steady state level (93, 113, 121-122).  
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1.12  Pharmacokinetics in special conditions 
1.12.1 Renal failure 
The kidney plays an essential role in the elimination of metformin, therefore the 
relationship between renal function impairment and metformin pharmacokinetics 
has been studied. 
Sirtori et al. (105) analysed the kinetic parameters of metformin in volunteers with 
normal and altered renal excretory function (estimated by creatinine clearance, 
Clcr). Following an IV injection to patients with impaired renal function the mean 
plasma t½ was 4.94 ±1.11 hr longer than for normal volunteers (p< 0.005). They   
also observed a significant inverse correlation between the plasma t1/2 of unchanged 
metformin and Clcr in individuals with normal and impaired renal function (r= 
0.88, p< 0.001). This significant correlation indicated the possibility of 
accumulation of metformin in severe renal impairment. If metformin was taken at 
eight hour intervals, the accumulation of unchanged drug after chronic treatment 
would be approximately 20% higher in a patient with t1/2 of 3 hours (i.e., with a 
Clcr between 30 and 60 mL/min) than in one with a normal t1/2 of 1.5 hour. 
Doubling of accumulation would occur only with t 1/2  values above 7 hours, i.e., in 
patients with Clcr of 30ml/min or less. Only patients with extremely impaired renal 
function are likely to significantly accumulate the drug.  
Another open labelled study (107) evaluated the independent contribution of kidney 
function and ageing on the pharmacokinetics of metformin. As shown in Figure 3, 
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the pharmacokinetics of metformin was influenced by kidney function. When the 
results for subjects with moderate and severe renal impairment were compared with 
those in the healthy young/middle age group, it was found that the total clearance 
was 77% lower in the latter group. As for metformin renal clearance, the result was 
estimated to be 78% lower in the moderate and severe renal impairment groups 
than in the healthy young/middle-age groups, again the difference was significant. 
Cmax was estimated to be 173% higher, and AUC was estimated to be 390% 
greater in subjects with moderate and severe renal impairment than in the healthy 
young/middle-age group, this was also noted to be a significant difference.  
Moreover, Tucker et al. (106) described the pharmacokinetics of metformin 
administered via oral and IV routes in normal subjects and in patients with type 
2DM. Three groups of subjects were studied, consisting of healthy male volunteers, 
patients who were newly diagnosed with type 2 DM and eight type 2 DM patients 
(with impaired renal function, estimated by Clcr, which ranged from 47 mL/min to 
107 mL/min). A highly significant linear correlation was observed between the 
renal clearance of metformin and creatinine clearance (r=0.85, p< 0.001).  
Data summarising these findings are shown in Tables 2-4. 
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Figure 3: Metformin plasma concentration versus (Vs) time curves of mean data after a 
single, 850 mg oral dose of metformin HCL (adapted from [(107)]) 
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 Table 2: Parameters describing the kinetics of metformin after a single oral 850 mg 
metformin dose  in healthy, moderate renal impairment, and severe renal impairment subjects 
[(107)] 
 Healthy 
volunteers 
Renal 
(moderate 
impairment) 
subjects 
Renal (severe 
impairment) subjects 
Number of subjects 
(n) 
21 4 6 
Clearance total 
(mL/min) 
1155 ±273 238.3 ±109.9 257.3 ±129 
Renal clearance 
(mL/min) 
636 ±84 108.3 ±57.2 129.5 ±90.3 
t1/2(hrs) 6.9 ±4.2 16.2 ±7.6 17.2 ±9.1 
C max (μg/mL) 1.39 ±0.33 4.12 ±1.83 3.93 ±0.92 
 
Table 3: Comparison between kinetic parameters of metformin between healthy volunteers 
and renal impaired subjects following IV administration of metformin [(105)] 
 Healthy volunteers Renal impairment subjects 
Number of subjects (n) 5 5 
Clearance total (mL/min) 441 ± 40 88.4 ± 11.8 
Renal clearance (mL/min) 335 ± 46 60.4 ± 78 
t ½ (hrs) 1.52 ± 0.13 4.94 ± 1.11 
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Table 4: Comparison between kinetic parameters of  metformin between healthy individuals 
and renal impairment subjects after oral administration [(106)] 
 Healthy volunteers Renal impairment subjects 
# of subjects 4 8 
Clearance total (mL/min) 1435.5 ± 370 718 ± 203 
Renal clearance (mL/min) 522 ± 201.5 224 ± 58 
t ½ (hrs) 5.7 ± 2.9 NA* 
C max ( μcg/mL) 2.06 ± 0.64 3.24 ± 1.46 
Dose (mg) 1850 ± 1 1000 
AUC -24 (μcg/mL.hr-1) 12.5 ± 4.17 24.84 ± 6.68 
*NA: not available 
1.12.2 Elderly patients 
Nearly 50% of individuals with type 2 DM are over the age of 65 years (123), and 
there is a number of changes often seen with advancing age that may complicate the 
management of DM, e.g. hypodipsia, anorexia, visual disturbance, altered renal and 
hepatic function, depression, impaired basoreceptor response and multiple 
medications (44). However, certain specific changes associated with physiological 
ageing have potentially greater effects on the metabolism of oral hypoglycaemic 
agents (124). The most important change interfering with the pharmacokinetic 
profile of metformin is the progressive decrease of renal function with ageing (107, 
125-126). Serum creatinine (Srcr) levels decrease with age because of the decline in 
lean body mass, despite an age-related decline in glomerular numbers and function 
(125, 127), therefore glomerular filtration rate (GFR) declines with age. As 
previously discussed in the study by Sambol et al. (107) the combined effect of 
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kidney function and age on the pharmacokinetics of metformin used multivariate 
regression analysis on the combined data of all groups. It showed that both renal 
function (as measured by Clcr) and age were predictors of metformin clearance. 
Whereas Clcr as a single covariate was significant, age was only significant when 
Clcr was considered. These results indicated that, given the same Clcr an elderly 
individual was expected to have a lower metformin clearance than a younger 
individual. The authors commented that it was unlikely that age had an effect on the 
clearance of metformin entirely independent of renal clearance; it was more likely 
that overall renal function and the function of various subcomponents (i.e., GFR 
and renal tubular secretion) may not be able to be predicted entirely from Clcr. 
They concluded that the prediction of metformin clearance was enhanced by adding 
age to Clcr as an independent variable, because in elderly individuals, relative to 
young, renal function was overestimated by Clcr alone.  
1.13  Metformin side effects 
The most common adverse effects due to metformin are gastrointestinal in nature 
and often occur during initial therapy (103, 128). These include diarrhoea, 
abdominal discomfort, anorexia, nausea and rarely, a metallic taste in the mouth 
(129-131). However, in order to minimize these adverse effects, metformin should 
be taken with meals, and as the symptoms are dose related, metformin should be 
started at a lower dose. More than 50% of patients can tolerate the maximum dose 
(2250 mg/day), but about 5% cannot tolerate any dose of metformin (128). 
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Metformin can also interfere with the absorption of vitamin B12 (86, 132) and 
folate (132).  
1.13.1 Lactic acidosis 
Lactic acidosis is a rare and potentially fatal metabolic condition that can occur 
whenever substantial tissue hypoperfusion and hypoxia exist (133-134). The 
mortality rate in reported cases is approximately 42-50% (129, 135). 
Lactate is produced from anaerobic glycolysis principally by the skeletal muscle, 
brain, erythrocytes and the renal medulla and eliminated by the liver, kidney and 
heart (136). The normal fasting serum lactate has a range of : 0.4 1.2 mmol/L 
(137). Pathological hyperlactataemia with acidosis may occur through over-
production of lactate (and hydrogen ions), reduced lactate clearance or a 
combination of both (133). It is a life threatening disorder of intermediary 
metabolism and defined as a metabolic acidosis in which the arterial blood lactate is 
greater than or equal to 5mmol/L and the arterial pH is less than or equal to 7.35 
(136, 138). Associated symptoms are nonspecific, but include malaise, myalgia, 
somnolence, abdominal discomfort, and respiratory distress. 
1.13.2 Types of lactic acidosis 
Classically lactic acidosis is subdivided into two groups: type A or anaerobic, and is 
due to hypoxia from the hypoperfusion of tissues, whereas type B or aerobic, is due 
to metabolic conditions such as liver disease, sepsis or DM. Both lead to lactic acid 
overproduction and /or defective excretion in the aerobic state (139). 
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1.14  Metformin –associated lactic acidosis (MALA)   
The true incidence of MALA is not known (140-141). The Food and Drug 
Administration (FDA) has estimated the rate of fatal and nonfatal lactic acidosis to 
be five cases per 100,000 persons treated over the course of one year (135). 
Population based studies have estimated a rate of two to nine cases of lactic 
acidosis in metformin users per 100,000 person years (142-143), while data from 
France, Sweden, and Switzerland suggested rates of 1 to 15 cases per 100,000 
person-years (144).  However, most of the reported cases have occurred in patients 
with severe acute conditions such as renal failure, septicaemia or cardiovascular 
collapse (shock), that could in themselves have caused lactic acidosis (128, 135, 
145-147). Phenformin, a biguanide agent, was withdrawn from the market because 
it was associated with a reported rate of lactic acidosis in 40-64 cases per 100,000 
patient-years (128-129, 139, 148).  However, metformin differs from phenformin in 
molecular structure and pharmacokinetics (129, 147, 149). Phenformin is a mono-
substituted compound and has a rather long side chain. Metformin (1,1-
dimethylbiguanide) is  bi-substituted and the methyl side chain is short (103). 
(Figure 4) The mono-substituted, long chain, lipophilic phenformin is metabolized 
by aromatic hydroxylation in the liver (103, 128, 150). In contrast, the bi-
substituted, short chain, hydrophilic metformin is not metabolized, and is 
eliminated by renal excretion (103, 151-152). These pharmacokinetic differences  
result in a poor binding of metformin to mitochondrial membranes , therefore 
metformin does not influence lactate turnover or oxidation in either basal or insulin- 
stimulated states (149). Thus, metformin does not increase lactate production in 
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skeletal muscle (153) and any metformin- related increase in blood lactate levels 
does not arise from peripheral tissues (103, 154). Data indicates instead that 
metformin increases lactate production via the extrahepatic splanchnic bed (130) 
with animal studies favouring the small intestine as the site of origin (154). The 
magnitude of this effect is known to be small when the drug is prescribed 
appropriately (129). Therefore, the incidence of metformin associated lactic 
acidosis was estimated to be 10-20 times lower than phenformin (144).  
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Figure 4: Chemical structural differences between  metformin and phenformin 
 
 
 
Bisubstituted with two small groups with 
less lipophilicity on the molecule 
Long lipophilic side chain causes it bind to 
mitochondrial membranes and to be 
metabolized by aromatic hydroxylation in the 
liver 
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1.15  Studies of MALA 
Numerous clinical studies, including randomized, double-blind, placebo-controlled 
trials, have demonstrated that metformin is safe to be used if contraindications and 
warnings are respected  (155) (156) (157) (158)  (86) (159). In all previous studies 
there was no case of fatal or nonfatal lactic acidosis reported in the metformin 
group, this was supported by a meta-analysis study performed by Salpeter et al. 
(140-141). They reviewed published reports of controlled trials and cohort studies 
to assess the risk of fatal and nonfatal lactic acidosis associated with metformin use 
in persons with type 2 DM. It was observed that when the data from cohort studies 
were combined with the prospective comparative trials there was no case of fatal or 
nonfatal lactic acidosis reported in either the metformin (totalling 35,619 patient-
years) or the non-metformin groups (representing 30,002 patient-years). When 
statistically analysed with 95% confidence, the upper limit for true incidence of 
metformin associated lactic acidosis was 8.4 cases per 100,000 patient-years, and 
the upper limit for the incidence of lactic acidosis in the non-metformin group was 
9 cases per 100,000 patient-years. When the combined data from metformin and 
non-metformin groups were considered together the upper limit for the true 
incidence of lactic acidosis in all patients with type 2 DM was 4.6 cases per 
100,000 patient-years. Tables 5, 6 and 7 describe the characteristics and limitations 
of MALA studies.  
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Table 5: Characteristics of MALA studies, with sample size, duration of the studies, inclusion and exclusion criteria’s, intervention and measured outcomes   
Study Design Duration # of subject Age (years) 
 Treatment Comparison combination  
Horton et al 
.(155) 
Randomized placebo 
controlled double-blind 
6 months 178 351 
 
172 56-59 
Herman et al 
.(156) 
Randomized controlled 
double-blind 
6 month 38 34 72 60 
COSMIC (157)  Randomized open label 12 month 7,227 1,505 NA ≥ 18 
Yki-Jarviene et 
al. (158) 
Randomized control 12 month NA 19 23 NA 
DeFranzo et al 
.(86) 
Randomized control 
multicenter 
29 weeks P1:143 
P2: 210 
P1: 146 
P2:  209 
P 2: 213 40-70 
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Table 6: Characteristics of MALA studies, with sample size, duration of the studies, inclusion and exclusion criteria’s, intervention and measured outcomes   
Study Interventions Outcomes Inclusion Exclusion 
Treatment Comparison 
Horton et al. 
(155) 
Metformin 500 mg three 
times/day  or metformin 
+ nateglanide 
Nateglanid or placebo HbA1c Type 2 DM Renal impairment, 
significant diabetic 
complications 
Herman et al 
.(156) 
Metformin dosage 
adjusted clinically 
glibenclamide HbA1c 
FBG 
Type 2 DM Contraindication to 
medication 
 
COSMIC (157) Metformin 500-2500 mg Usual care HbA1c 
FBG 
Type 2 DM Normal renal function, 
normal hepatic 
function, no history of 
metabolic acidosis 
Yki-Jarviene et 
al. (158) 
Bed time insulin + 
metformin 2000 mg/day 
Bed time insulin + 
glyburide 
Bedtime insulin+ metfromin 
+ glyburide 
Bed time insulin + morning 
insulin 
FBG, insulin sensitivity Type 2 DM 
BMI<30 kg/m2 
FBG> 8 mmol/L 
Congestive heart 
failure (CHF) 
MI 
Stroke 
Epilepsy 
Liver disease 
Srcr < 120μ mol/L 
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Proliferative 
retinopathy 
Severe maculopathy 
Excessive alcohol 
consumption >20 
g/day 
DeFranzo et al.  
(86) 
Metformin 2550 and 
2500 mg 
 
Glyburide and Placebo FPG 
BMI 
Type 2 DM 
Obese 
FPG>7.8 mmol/L 
Srcr ≤ 124 μmol/L 
men, ≤115μmol/L 
women 
Normal liver 
function 
Symptomatic 
cardiovascular disease 
Diastolic blood 
pressure (BP) > 100 
mmHg 
Insulin therapy 
≥ 3 ounce alcohol/day 
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Table 7: limitations of MALA studies and the National Health and Medical Research Council (NHMRC) level of evidence for each study 
Study Limitations NHMRC level of evidence (160) 
Horton et al. 
(155) 
Maximum metformin dose used in the study was lower than what is normally 
used in clinical practice (1500 compared to 2500-3000 mg/day). 
Excluded patients who are contraindicated to metformin use. 
II (randomised controlled trial) 
Herman et al 
.(156) 
Small sample size in each assigned group. 
The conditions of contraindications to the drug were not clearly defined. 
Dietary habits and physical activity were not mentioned which might contribute 
to weight loss, thus increase lactate levels and affect the results and outcomes.  
Excluded patients who are having contraindication to metformin use such as 
renal impairment.  
II (randomised controlled trial) 
COSMIC (157) Exclusion of patients with abnormal hepatic or renal function from the study 
which themselves might cause lactic acidosis. 
III 2 (comparative study with concurrent 
controls) 
Yki-Jarviene et al 
(158) 
Small sample size in each group.  II (randomised controlled trial) 
DeFranzo et al. 
(86) 
Exclusion of any conditions which might be regarded as a contraindication to 
metformin use. 
 
II (randomised controlled trial) 
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1.16  Is it safe to use metformin with the presence of 
contraindications? 
Classically metformin was classified to cause type B lactic acidosis , however, data 
from one study (120) indicated that pure type B lactic acidosis occurred only in 
exceptional cases and that most metformin treated patients present with a mixed ( A 
+ B ) lactic acidosis ( i.e. metformin accumulation with concurrent disease ) (148). 
As indicated earlier lactic acidosis with metformin therapy has been found to occur 
exclusively in patients with contraindications to the drug’s use, which leads to the 
supposition that this adverse effect might be avoided through strict adherence to 
prescribing guidelines (153). However, in clinical practice it has been shown that 
prescribing doctors tend not to always comply with the recommended 
contraindications to metformin use listed in the guidelines (161), believing that 
these have been developed from experience with phenformin. Therefore it has been 
argued that metformin contraindications are overzealous (141).  
In order to weigh the risk and benefit of metformin use with stated 
contraindications in the available guidelines, several clinical studies have evaluated 
the safety of continued use of metformin in patients with contraindications to 
metformin.  Rachmani et al. (162) recruited 393 patients who had been treated with 
metformin alone or in combination with other hypoglycaemic agents, and who were 
found to have one or more contraindications to metformin according to the 
guideline recommendations (147, 163). Patients were then randomized to continue 
or to stop metformin. The patients were followed annually or more frequently if 
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clinically indicated. The authors concluded that metformin was safe in patients with 
recognized contraindications to its use. Moreover, they observed that 
discontinuation of metformin resulted in weight gain, worsening of glucose control 
as evidenced by a rise in HbA1c level, and a modest rise in low density lipoprotein 
(LDL) compared to those who continued the drug. These disadvantages of 
discontinuance were balanced by no advantage. They further recommended that 
patients who have been on metformin and who tolerated the drug well, should 
probably be allowed to continue the drug despite the development of one or more of 
the contraindications stated in the available guidelines.  
Another population based study of adherence to prescribed guidelines (164), 
retrospectively studied the incidence of contraindications to metformin in 4600 
patients with type 2 DM using metformin. They observed that 24.5% of patients 
receiving metformin had contraindications to its use which was in accordance with 
advice in the manufacturers data sheet and the British National Formulary (BNF) 
(165). One episode of lactic acidosis was identified in the study group, this was a 
72-year-old patient on metformin with previously normal renal function (creatinine 
78 μmol/L, 20 days previously), who was admitted to hospital with an extensive 
myocardial infarction (MI) demonstrated on electrocardiography who then 
developed acute renal failure (urea 31.2 mmol/L, creatinine 152 μmol/L), lactic 
acidosis (serum lactate 17.9 mmol/L) and died the same day. Based on this patient’s 
clinical scenario, they suggested that it was likely that the lactic acidosis was 
secondary to the MI rather than a direct consequence of inappropriate metformin 
use. They concluded that patients commonly remained on metformin despite the 
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development of conditions considered in the data sheet to be contraindications. 
They observed that in their region at least, metformin was rarely stopped when 
contraindications developed, but despite this, lactic acidosis remains a rare 
complication.  
Moreover, from 164 prospective studies reviewed recently in a meta-analysis study 
(141), they observed that 156 (95%) studies allowed for the inclusion of patients 
with at least one contraindication to metformin, 16% of all participants were 
estimated to be older than 65 years with no adverse effects observed among those 
groups. However, they concluded that it was not clear how many participants with 
contraindications were included in the trials; hence the safety of metformin in the 
presence of standard contraindications cannot be assessed.  
A recent study from the UAE (166) assessed the risks and benefits of metformin 
use in diabetics with the presence of contraindications; 106 diabetic patients were 
recruited in the study. Metformin plasma concentration, lactate concentration, C-
peptide, HbA1c, and insulin were measured. Current medical condition, 
demographic data, and current medication were also reported. They observed that 
almost 67% of the patients had medical conditions that hindered metformin usage, 
yet no case of lactic acidosis was observed or reported in their patients. They 
concluded that the prescribing patterns did not conform to the guidelines, and that 
the available guidelines appeared to be misleading. They recommended that the 
contraindications to metformin as stated in the guidelines should be reviewed, and 
unambiguous guidelines were required to prescribe metformin rationally. 
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The above mentioned studies failed to confirm an absolute safety of metformin in 
the presence of contraindications to its use. However, in order to confirm 
metformin safety and to maximize its clinical efficacy and minimize the unwanted 
side effects, a large prospective population study to investigate factors might 
positively or negatively impact on the occurrence of fatal adverse effects such as 
lactic acidosis in the presence of other contraindications is required.  
1.17  Mechanism of action of metformin 
Despite being in the market for decades, the molecular site of action of metformin 
has been a research area of interest. Unlike sulphonylurea agents, the mechanism of 
action of metformin does not involve the stimulation of insulin secretion by the 
endocrine pancreas, although it’s clinical efficacy requires the presence of insulin, 
hence, hypoglycaemia is not observed (86, 131, 167-168). Whereas, most studies 
have shown that the glucose lowering effects of metformin are secondary to a 
decrease in hepatic glucose production (86, 130, 149, 167-169) a significant body 
of data has also suggested that metformin increases glucose disposal in skeletal 
muscle (128, 130-131, 149, 170).  
Adenosine monophosphate activated protein kinase (AMPK) provides a candidate 
target capable of mediating the beneficial metabolic effects of metformin. AMPK 
belongs to the family of energy-sensing enzymes that are activated by cellular 
stresses resulting in Adenosine Tri-Phosphate (ATP) depletion, thus acting like a 
“fuel gauge” (171-173). On activation, AMPK functions to restore cellular ATP by 
inhibiting ATP consumption processes, but accelerating ATP generation processes. 
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The cascade is activated by physiological stress, such as contraction or prolonged 
exercise (174-176) or electrical stimulation in skeletal muscle (174, 176-177), 
ischemia in heart muscle (178-179), heat shock (180) as well as through inhibition 
of the tricarboxylic acid cycle or oxidative phosphorylation (181).  
AMPK is a heterotrimeric protein comprising catalytic subunit (α) and two 
regulatory subunits (β and γ)(182-183). The regulatory subunit plays an important 
role in maintaining stability of the heterotrimer complex (171, 183). Both α and β 
subunits have two isoforms each, AMPKα1 and AMPKα2, and AMPKβ1 and 
AMPKβ2, while γ subunit exists in three isoformic forms, AMPKγ1, AMPKγ2, and 
AMPKγ3 (184-186). AMPKα1 is widely distributed, while AMPKα2 is found 
mainly in skeletal muscle, heart, and liver (185) .  
AMPKα co nsists o f 5 4 8 amino  acid s and  it contains a catalytic domain (1-312 
amino acid), an autoinhibitory domain (312-392 amino acid), and a subunit binding 
domain (392-548 amino acid)(185, 187). The catalytic domain has the site of 
phosphorylation at Thr172 which is required to be phosphorylated for its activation 
by AMPK kinase. Removal of both the autoinhibitory domain and subunit binding 
domains leads to constitutive active AMPK retaining one third of activity compared 
to full AMPK complex whereas, removal of subunit binding domain leads to a 
complete loss of activity (187-188).  AMPK can also be activated through other 
mechanisms, allosteric activation, and a decrease in the inhibitory action of 
phosphatases(171, 182, 189). The increase in AMPK activity results in the 
stimulation of glucose uptake in muscle, fatty acid oxidation in muscle and liver, 
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and the inhibition of hepatic glucose production, cholesterol and triglyceride 
synthesis, and lipogenesis (190-192). 
The activation of AMPK initiates a cascade of metabolic effects that resembles 
metformin gluco-regulatory effects; therefore, several in vitro and in vivo studies 
have tested the hypothesis that activation of AMPK mediates the beneficial effects 
of metformin.  
Zhou et al. (193) postulated that AMPK activation was the mechanism of 
metformin action. They measured the activity of AMPK in cultured rat hepatocytes 
and isolated muscles that were incubated in control, 5-aminoimidazole-4-
carboxamide ribonucleoside (AICAR), and metformin media. They found that after 
one hour treatment, 500 µm metformin was required to significantly activate 
AMPK, whereas after a 7 hour treatment, 50 µm was sufficient to significantly 
activate the enzyme; a result that was consistent with the time dependent effects of 
metformin. They also found that metformin as well as AICAR induced AMPK 
Thr172 phosphorylation demonstrated by using an anti-phospho-AMPK antibody. 
Moreover, both metformin and AICAR were able to inhibit cumulative glucose 
production in primary cultured rat hepatocytes stimulated with glucagon, and 
incubation of isolated muscles with metformin resulted in an increase in the activity 
of both catalytic subunits of AMPK. Importantly, co-incubation of hepatocytes with 
compound C (6-[4-(2-Piperidin-1-yl-ethoxy)-phenyl])-3-pyridin-4-yl-pyrazolo[1,5-
a] pyrimidine), a potent reversible AMPK inhibitor, was able to reduce the effects 
of metformin to decrease glucose production in these cells. In conclusion, the study 
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showed that metformin significantly increased AMPK activity in cultured rat 
hepatocytes and isolated muscles, and the activation of the enzyme was associated 
with diminished glucose production by the hepatocytes and higher muscle glucose 
uptake.  
In order to investigate whether the activation of AMPK by metformin was a likely 
mechanism for its metabolic effects in subjects with type 2 diabetes, Musi et al. 
(194) examined if treatment with metformin modified the activity of the AMPK α1 
and α2 isoforms in skeletal muscle. Eight subjects with type 2 diabetes (seven 
males and one female) were studied before, during, and after 10 weeks of treatment 
with metformin. The subjects discontinued their antidiabetic therapy three weeks 
before the study. Three days before the study, they were given a diet composed of 
55% carbohydrates, 30% fat, and 15% protein. Blood samples for FPG, HbA1c%, 
lipids, lactate, and free fatty acids, were taken at zero week, and week 10 of the 
study. Muscle biopsies were taken at week zero, week four, week 10 three hours 
after a 1000 mg dose of metformin to insure metformin concentrations were at their 
highest (tmax 2.5-3.3 hr), and to determine whether potential changes in AMPK 
activity would persist when blood metformin concentrations were low. Six subjects 
continued treatment at 1000 mg twice a day and underwent a fourth muscle biopsy 
within seven days of the 10 week biopsy. The subject’s commenced metformin on 
500 mg oral dose once daily, the dose was then increased weekly to a maximum of 
1000 mg twice daily. All subjects tolerated metformin without any adverse effects. 
They found that AMPK α2 activity increased by 52% after four weeks of treatment 
and further increased to 80% after 10 weeks of treatment. Interestingly, the 
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activation of AMPK α2 by metformin continued after an overnight withdrawal. In 
contrast, AMPK α1 activity did not change during treatment. Together, these 
findings in animal tissue (193) and human skeletal muscle (194) strongly supported 
the role of AMPK in mediating the metabolic actions of metformin.     
The mechanism by which metformin activates AMPK remains controversial, 
although some studies (195-196) have demonstrated that metformin activates 
AMPK by decreasing cellular energy by acting as an inhibitor of complex 1 of the 
respiratory chain, which might also explain metformin associated lactic acidosis. 
However, recent studies (197-201) do not support this model especially since 
metformin in these studies activated AMPK without affecting the Adenosine Mono-
Phosphate (AMP)/ATP ratio. Alternatively, genetic and biochemical studies 
reported that serine threonine kinase (STK11/LKB1) can phosphorylate and 
activate AMPK, hence emphasized the role of LKB1 in metformin action.  
Summary of the chain for metformin action: 
• AMPK is activated by ATP depletion. 
• Upon activation AMPK decreases ATP consumption and increases ATP 
generation. Acting like a “fuel gauge”, as shown in Figure 5. 
• AMPK activation results in (Figure 6) -:  
 Stimulation of glucose uptake in muscle. 
 Stimulation of fatty acid oxidation in muscle and liver. 
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 Inhibition of hepatic glucose production. 
 Inhibition of cholesterol and triglyceride synthesis. 
 Inhibition of lipogenesis. 
• Metformin gluco-regulatory effects resemble activated AMPK metabolic 
effects.  
• AMPK activation was postulated as a mechanism of metformin action. 
• AMPK activated by phosphorylation which is mediated by LKB1. 
 
 
 
 
 
 
 
 
 
 
44 
 
AMPK 
 
 
ATP consumption process ATP generation process 
 
 
 
 
         
 
Figure 5: Diagram illustrating how AMPK acts as a “fuel gauge”.  
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Figure 6: Metabolic cascade upon AMPK activation  
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1.17.1 STK11/LKB1 
LKB1, a 50-KDa serine/ threonine kinase, was originally identified as the product 
of the gene mutated in the autosomal dominantly inherited Peutz-Jeghers cancer 
syndrome (PJS) (202-203). A number of groups have demonstrated that knocking 
out one of the LKB1 alleles in mice is sufficient to induce a cancer syndrome 
similar to PJS in humans (204). In resting cells, LKB1 is reported to be 
predominantly located in the nucleus (204-206). LKB1 is a heterotrimeric complex 
with regulatory proteins termed STRAD and M025, which are required for its 
activation and cystolic localization (204, 206). LKB1 has been shown to mediate 
Thr172 phosphorylation of AMPK both in vitro and in intact cells (197, 200). In 
vivo studies have shown that mice lacking LKB1 expression have significantly 
inhibited AMPK activity (198). Importantly metformin has shown to activate 
AMPK in wild type mice but failed to activate AMPK in livers deficient in 
LKB1(201, 207). Moreover, metformin treatment lowered blood glucose in obese 
mice by 40%, however, there was no reduction in blood glucose in the mice in 
which LKB1 had been deleted in the liver (201, 207). Xie et al. (207) demonstrated 
that; in order to activate AMPK, LKB1 must be exported from the nucleus into the 
cytoplasm. They used specific antibodies against LKB1, and found that LKB1 was 
located mainly in the nucleus of non-stimulated human umbilical vein endothelial 
cells. However, in the cell treated with metformin, LKB1 was mainly detected in 
the cytosol; an observation that was confirmed by Western blot analysis. 
Accordingly, they concluded that, metformin increased LKB1 phosphorylation at 
ser 428 that induced the translocation of LKB1 from the nucleus to cytoplasm 
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where it activated AMPK. Moreover, they observed that mutation of ser 428 into 
alanine was able to prevent this translocation and hence abolished metformin 
enhanced association of LKB1 with AMPK. Thus, ser 428 phosphorylation might 
play a crucial role in regulating AMPK activation. Therefore knowing the allele 
frequencies of this mutation among different ethnic groups, as well as identifying 
the significance of this mutation in the clinical setting will help the clinicians to 
predict or modify a patient’s response to metformin therapy.  
1.18  Inter-individual response to metformin 
Inter-individual differences in response to metformin can be due to a variety of 
factors, including age (107), renal function (105-107) and metformin dose (208-
209). Pharmacogenomic studies indicate that genetic differences should be taken 
into consideration when large inter-individual variability in the intensity and 
duration of drug effects and side effects are observed. Several genetic studies have 
revealed that genetic differences contribute to the variability of metformin effects 
(210-211). As discussed previously, metformin is a strong base that protonated at 
physiological pH. Metformin has been well characterized in vitro as a substrate of 
OCTs (20, 212-214), including OCT1 (215-217), which is primarily expressed in 
the liver (218-220) and its paralog OCT2 (18-19, 221), which is mainly expressed 
in the renal basolateral membrane (18, 221-222). In contrast, in vivo studies have 
shown that the uptake of metformin was higher in rat OCT1 transfected cells than 
in vector transfected cells. Moreover, it was observed that the plasma and liver 
concentrations of metformin were three times higher in OCT1-/- mice than 
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OCT1+/+ mice (215). These results were compatible with other in vivo and in vitro 
studies (216-217, 223-224). 
The OCT1 and OCT2 transporters are subtypes of the solute carrier transporter 
family (SLC), subfamily 22 (SLC22A) (225-226). The SLC22A family includes 
three organic cation transporters, OCT1, OCT2, and OCT3 (225, 227). In human 
the genes coding for OCT1, OCT2, and OCT3 are localized within a cluster on 
chromosome 6.q26-7 (228-230). Each of the three genes comprises 11 exons and 10 
introns (229, 231-232) 
Several genetic and molecular studies have demonstrated that OCT genes exhibit 
polymorphic variation in the coding region (24-27). In order to investigate the 
pattern of polymorphisms exhibited with OCT1 and OCT2 genes, various studies 
have screened for genetic variants in different populations. Recently, genetic testing 
was performed with 57 Caucasian subjects. A number of 25 single nucleotide 
polymorphisms (SNPs) have been identified in the OCT1 gene, which were 
dispersed through exons, introns, and the promoter region (24-25). Eight of these 
polymorphisms were non-synonymous, resulting in an amino acid exchange of the 
OCT1 carrier protein. Subsequent functional analysis of 5 coding variants revealed 
diminished in vitro transport activity of one variant and nearly completely lost 
uptake function of two other mutants. Another study investigated for novel SNPs 
by sequencing all the exons and the surrounding introns of OCT1 from 116 
Japanese individuals (26). Twenty variants were found including 7 novel ones. 
Eight detected variants were similar to the previous Caucasian study with different 
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frequencies between these two populations. One novel non-synonymous SNP that 
resulted in amino acid substitution was identified in one heterozygous subject, 
however, the functional effect of this SNP on transport activity was not 
investigated. 
Moreover, Shu et al. (25) screened all exonic, introns, and the promoter region of 
the OCT1 gene. They detected 14 non-synonymous polymorphisms and one 
deletion variant from five different ethnic groups, African-Americans (100 
subjects), European- Americans (100 subjects), Asian- Americans (30 subjects), 
Mexican – Americans (10 subjects), and Pacific- Islanders (7 subjects). The allele 
frequencies of these SNPs were different among all five different ethnic groups 
(Table 8). Of 14 variants, five exhibited decreased transport activities (OCT1-
R61C, OCT1-G220V, OCT1-P341L, OCT1-G401S, and OCT1-G465R) while one 
had increased transport activities (OCT1- S14F) which was exclusively found in the 
African-American population sample.    
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Table 8: The allele frequencies of OCT1 SNPs reported among five different ethnic groups in 
the Shu et al. (25) study. 
 Allele frequency‡  
Amino 
acid 
change 
Total 
(n= 494) 
AA 
 (n=200) 
EA  
(n=200) 
AS 
(n=60) 
ME 
(n=20) 
PA  
(n= 14) 
Function* 
S14F 0.013 0.013 0 0 0 0 +/+ 
R61C 0.031 0 0.072 0 0.056 0 +/- 
G220V 0.002 0.005 0 0 0 0 - 
P341L 0.047 0.082 0 0.117 0 0 +/- 
G401S 0.008 0.007 0.011 0 0 0 - 
G465R 0.016 0 0.04 0 0 0 - 
‡ AA: African American; EA: European American; AS: Asian American; ME: Mexican 
American; PA: Pacific Islander, n is the number of chromosomes.  
* ++: increased function relative to the reference OCT1; +: function similar to that of 
reference OCT1; +/-: reduced function; -: no function. 
 
Recently Kang et al. (29) evaluated genetic polymorphisms of OCT1, and OCT2 
genes in healthy Korean subjects and investigated the functional properties of the 
non-synonymous SNPs. They screened all 11 exons and flanking intronic 
sequences of 150 Korean subjects. Four non-synonymous SNPs were identified of 
the OCT1 gene (F160L, P283L, P341L, and M408V). Two of them showed 
decreased transport activities (P283L and P341L). Whereas, they reported three 
non-synonymous SNPs of the OCT2 gene (T199I, T201M, and A270S) of which 
all showed decreased transport activities. Furthermore, they compared the allele 
frequencies of the major functional SNPs of the OCT1 and OCT2 genes in the 
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study population with three other ethnic groups, namely; 100 Vietnamese, 100 
Chinese, and 100 white German. They observed that OCT1-P283L, OCT2-T199I, 
and OCT2-T201M SNPs were detected very rarely and showed no differences 
between Asians and white Germans. The allele frequencies of OCT1-P341L, and 
OCT2-A270S in the Korean population were similar to those in other Asian 
populations and significantly higher than those in the white German population. 
Despite being genetically classified as Caucasian, one genetic variant found in the 
white German population (OCT1-P341L) was not detected in a white European- 
American population (24-25). In addition, the OCT2-A270S mutation revealed 
different allele frequencies between the white European- American and white 
German populations (15.7% (233), 2.5%, respectively). Kang et al. concluded that 
OCT1 and OCT2 genes exhibited genetic polymorphisms in Korean populations 
that were similar to those in other Asian populations but different than white 
German populations. The functional analysis of the detected non-synonymous 
SNPs showed significant decreased transport activities. The results emphasize the 
role of genetic factors in observed inter-individual variability with response to 
clinically used drugs. Interestingly, the allele frequencies of major SNPs could vary 
among the same descent. However, all of the above mentioned studies have not 
examined the functional consequences of synonymous SNPs on the OCT1 substrate 
transport activity, and haplotype linkage analysis was not performed on the detected 
SNPs.   
In order to investigate the role of genetic variation of the OCT gene on metformin 
pharmacokinetics, several in vivo and in vitro studies have been undertaken. 
52 
 
Recently, Shu et al. (223) measured the cellular uptake of metformin in primary 
mouse hepatocytes.  They have found that metformin uptake was significantly 
lower (3.4 fold, p< 0.0001) in OCT1-/- cells compared with those in cells with a 
functional OCT1 allele, and the hepatic accumulation was significantly greater in 
wild type mice (4.2 fold, p< 0.001) than OCT1-/- mice. Moreover, the 
phosphorylation of AMPK by metformin was substantially reduced in OCT1-/- 
hepatocytes in comparison to those in wild type hepatocytes. They also observed 
that metformin significantly suppressed glucagon stimulated glucose production in 
hepatocytes from wild type mice (30% suppression, p< 0.001) but not in 
hepatocytes from OCT1-/- mice. Based on these results they concluded that OCT1 
plays a key role in determining one of the major pharmacologic effects of 
metformin, inhibition of hepatic gluconeogenesis. In order to study the effect of 
non-synonymous OCT1 polymorphism on metformin uptake and response in 
cellular assays, Shu et al. (223) measured the uptake of metformin in stable cell 
lines expressing empty vector, OCT1 reference, and in 12 OCT1 non-synonymous 
variants. Compared with OCT1 reference, seven OCT1 variants exhibited 
significantly reduced or lost metformin uptake, despite similar mRNA levels. 
Finally they compared the clinical effects of metformin in an oral glucose tolerance 
test (OGTT) in volunteers carrying the reference OCT1 allele and those carrying 
the OCT1 polymorphisms. They found that after OGTT the glucose plasma levels 
and plasma glucose AUC in volunteers carrying reference OCT1 alleles and those 
carrying a reduced function polymorphism of OCT1 were similar. However, 
volunteers with reference OCT1 alleles had significantly lower plasma glucose 
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levels than those carrying OCT1 polymorphisms.  The results of this study showed 
that OCT1 is required to facilitate cellular uptake of metformin, and genetic 
polymorphisms of the OCT1 gene may contribute to a reduced therapeutic response 
to metformin.  
As noticed, the above study was unable to determine the effect of genetic variation 
in the OCT1 gene on the pharmacokinetics of metformin, therefore Shu et al. (32) 
recently conducted another study in 20 healthy European American volunteers. 
Subjects were classified into OCT1 variants (n= 12) and reference group without 
OCT1 variant (n= 8). All subjects received two separate doses of oral metformin 
850 mg and 1000 mg. The plasma concentrations of metformin were measured for 
24 hours after the second dose. They found that metformin plasma concentrations, 
AUC, and Cmax were significantly higher in the individuals in the OCT1 variant 
group than those in the OCT1 reference group (p< 0.05, p= 0.01, p= 0.004 
respectively). Moreover, subjects with variant OCT1 showed significantly lower 
volume of distribution compared to those in the OCT1 reference group (p= 0.022). 
Similar trends were observed in an animal study as OCT1-/- mice (n= 6) tended to 
have higher metformin plasma concentrations, AUC, and Cmax compared to those 
in OCT1+/+ mice (n= 5). Unlike the previous study, this study showed that the 
pharmacokinetics of metformin was significantly affected by OCT1 activity or 
genotype in healthy subjects. However, this study was conducted in healthy 
volunteers with a small sample size, and in order to verify the role of OCT1 
polymorphism in metformin action a large study on diabetic patients is required. 
Moreover, this study has not examined the functional consequences of synonymous 
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SNPs in the studied population that might reveal an association with metformin 
action on recruited subjects.     
In another study, the role of OCT1 polymorphisms on the clinical response to 
metformin therapy was studied in diabetic patients (21). Patients were classified as 
responders (n= 24) or non-responder (n= 9) to metformin therapy. The 
classification was based on their HbA1c results after more than three months of 
metformin treatment. Unpredictably, they observed no significant contribution of 
OCT1 polymorphisms to metformin efficacy. The discrepancy between Shikata et 
al. (21) and Shu et al. (32) results can be due to many reasons. Firstly, they 
followed different approaches to identifying patients, because Shu et al. (223) used 
OCT1 genotype while Shikata et al. (21) used metformin response (phenotype- 
genotype study), and therefore the relative contribution of OCT1 is unknown. 
Secondly, the studies were conducted in different ethnic groups having different 
genetic backgrounds (European American, Japanese subjects) hence, as discussed 
earlier, the allele frequencies of major SNPs could vary among the same descent 
and the role of these SNPs might be clinically different among different subgroups. 
Finally, both studies had small numbers of subjects (20 and 33 patients 
respectively) and in order to confirm the role of genetic polymorphism in drug 
therapy larger sample sizes are usually required. 
A recent study investigated the effect of genetic polymorphisms in the OCT1, 
OCT2, and OCT3 on the renal clearance of metformin (22). They analysed all 
known non-synonymous coding variants with frequencies >0.5% among 103 
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unrelated healthy, male Caucasian volunteers. They observed that there were no 
significant associations between the renal clearance of metformin and the variants 
analysed in the OCT2 and OCT3 genes. On the contrary, they found that two SNPs 
in the OCT1 gene were significantly associated with the renal clearance of 
metformin, namely; synonymous Ser (rs1867351) and non-synonymous 
465Gly>Arg SNPs (p= 0.03 and p= 0.003 respectively). However, after adjustment 
for age and Clcr, the significance of the association between rs1867351 SNP and 
metformin renal clearance was no longer evident. Subsequently, they analysed the 
combined effect of the four amino acid variants known to abolish OCT1 activity 
partially (Met420del) or fully (Arg61Cys, Ser401Gly, and Gly465Arg). They found 
that the renal clearance of metformin increased significantly with the number of 
inactive OCT1 alleles (p= 0.038), and the association remained significant after age 
and Clcr adjustments (p= 0.032). They also found that the net clearance by tubular 
secretion of metformin increased significantly with the number of inactive alleles. 
In order to explain the association between OCT1 polymorphism and the renal 
clearance of metformin, they further analysed OCT1 mRNA expression in the 
kidney in relation to liver and small intestine. It was found that the highest OCT1 
mRNA expression was observed in the liver, and the second highest OCT1 
expression was found in the kidney, which was fivefold higher than in the small 
intestine. They suggested that OCT1 localization in the luminal membrane in distal 
tubules may contribute to metformin reabsorption in the tubule, thus OCT1 genetic 
variations were associated with increased renal elimination of metformin. In 
contrast, they were unable to confirm the effects of genetic variations in OCT2 on 
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renal clearance. This study was conducted on young healthy volunteers, and it only 
studied the effect of genetic variations of the OCT gene on renal elimination of 
metformin that might be affected by other variables such as GFR which was not 
investigated.  
As discussed previously, GFR declines with age (107, 125-127) and diabetes by 
itself may reduce renal function and cause nephropathy (90, 234-235), and as it was 
shown the authors in the above mentioned study failed to associate OCT2 genetic 
variations and renal elimination of metformin. This indicates that GFR may play an 
important role that overcomes OCT2 contributions to renal elimination of 
metformin especially in diabetic patients.      
In contrast, those with OCT1 gene, human genetic variants of OCT2 were 
investigated comprehensively by screening all 11 exons of the gene as well as 
flanking intronic sequence in a collection of 247 ethnically identified genomic 
DNA samples (233). Twenty eight variable sites were identified, of which 16 were 
coding region variants and 12 were non-coding variants. Eight of the variants 
caused amino acid changes, while one variant was a single nucleotide insertion 
(134-135insA) that leads to a premature stop codon at amino acid position 48. Four 
of the non-synonymous variants, Met165Ile, Ala270Ser, Arg400Cys, and 
Lys432Gln, were polymorphic, with ethnic-specific allele frequencies ≥1%. The 
remaining four non-synonymous variants, Pro54Ser, Phe161Leu, Met165Val, and 
Ala297Gly, as well as the insertion variant were found on only one of 494 
chromosomes screened. Met165Ile and Arg400Cys were present only in the 
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African-American population sample, and Lys432Gln was present in both the 
African-American and Mexican-American population samples. Ala270Ser was 
present in all of the populations screened and had a particularly high allele 
frequency over all populations (12.7%). Leabman et al. determined the activity of 
the four polymorphic non-synonymous variants of OCT2 and observed that all of 
these variants retained function as measured by uptake of the prototypical organic 
cation substrate, [3H]-1-methyl-4-phenylpyridinium (MPP+), in Xenopus laevis 
oocytes expressing the variant transporters (233). However, differences in MPP+ 
uptake activity and kinetic differences in interactions with organic cations was 
observed for the common variants. The 134-135insA variant identified appeared to 
be a loss of function variant as assayed by MPP+ uptake in oocytes; individuals 
with this variant may exhibit reduced renal clearance of organic cations.  
The contribution of a genetic component to variation in the renal clearance of 
metformin was estimated to be particularly high (>90%) (210-211). Another study 
of six monozygotic twins showed that genetic factors contributed substantially to 
the renal clearance of metformin (236).  
Moreover, the OCT2 gene polymorphisms were detected in a group of 48 unrelated 
Japanese individuals (27) and 116 arrhythmic Japanese patients (28, 237). In the 
former study, 27 SNPs and 5 deletion polymorphisms in the OCT2 gene were 
identified (27). Two synonymous variants, also reported by Leabman et al.(233) 
were identified at amino acid positions 130 and 150. The remaining SNPs and 
deletion polymorphisms appeared in introns, 3` untranslated regions and 3` flanking 
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regions of the OCT2 gene. In the later study, 33 genetic variants including 14 novel 
ones were found (28, 237). Two non-synonymous were identified (Thr199Ile and 
Thr20Met) and other SNPs, insertion, and deletion polymorphisms were located in 
exons, 3`-untranslated region of exon 11, introns, and 3`-flanking region. 
Functional effects of these polymorphisms have not been investigated.  
Unlike the OCT1 gene, fewer studies have evaluated the effect of OCT2 variants on 
the in vivo pharmacokinetics of metformin, and most of these studies were on an 
Asian population.  
As discussed, Shikata et al. (21) assessed the functional significance of genetic 
polymorphisms of the OCT1 gene with regards to the efficacy of metformin in 
Japanese diabetic patients, at the same time they also assessed that with OCT2 
polymorphisms. They observed two non-synonymous variants with the OCT2 gene 
(T201M, and A270S) and the prevalence of these variants were not different among 
responders and non-responders. However, the discriminant functional analysis 
found one of the OCT1 variants as a positive predictor of metformin efficacy 
(M408V) but none of the OCT2 variants were shown to be predictors for metformin 
efficacy. However, this study recruited only a small number of subjects, and 
utilized a phenotype-genotype approach to investigate the role of OCT1 and OCT2 
genes on metformin effects; therefore the relative contribution of OCT2 was 
unknown. Moreover, OCT2 is mainly expressed in the renal basolateral membrane 
making it more reliable to investigate the functional analysis of OCT2 variants with 
regards to metformin pharmacokinetics, namely excretion and its role with 
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metformin accumulation but not with metformin action which is primarily 
facilitated by the OCT1 gene. Furthermore, they haven’t measured metformin 
plasma levels to estimate the relationship between OCT2 variants and inter-
individual variation to metformin therapy.  
Some of these drawbacks were considered in a recent study (238) that evaluated the 
effect of genetic variants of the OCT2 gene identified in a Korean population on the 
in vitro transport activity of metformin and on the in vivo pharmacokinetics of 
metformin in healthy human subjects. They determined metformin uptake in cell 
lines that expressed the OCT2 reference and OCT2 variants. It was shown that 
metformin uptake mediated by the OCT2 reference gene was saturable and higher 
than that mediated by OCT2 variants, and the intrinsic clearance of metformin was 
lower in OCT2 variants expressing cells in comparison with that in OCT2 reference 
expressing cells. In order to evaluate the in vivo pharmacokinetics of metformin in 
healthy human subjects, 26 subjects were recruited in the study; 9 in the OCT2 
reference group, and 17 in the OCT2 variants group. A single 500mg dose of 
metformin was given to the subjects, blood and urine samples were collected after 
12 hours. The pharmacokinetic parameters showed significant differences among 
reference and variant groups. Subjects with OCT2 variant had significantly higher 
Cmax and AUC values, but lower clearance, volume of distribution, renal 
clearance, and secretion clearance values as compared to the reference group. In 
conclusion, the results of the study indicated that the genetic variations of OCT2 
gene will result in decreased renal excretion of metformin and subsequently 
increased metformin plasma concentration. Therefore, genetic variants of OCT2 
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should be considered with metformin therapy. However, small sample sizes and the 
use of healthy subjects were drawbacks. 
Recently, Chen et al. (23) determined the effect of the most common genetic 
variation in OCT2 (A270S) on the renal elimination of metformin in healthy 
volunteers of 94 unrelated European and 66 unrelated African-American ancestries. 
Subjects were given a single oral dose of 850mg of metformin. Blood and urine 
samples were drawn at different times for metformin pharmacokinetic parameters 
and DNA genotypes. By using multivariate analysis, they tested the effect of the 
OCT2 genotype, sex, age, race, and Clcr on metformin renal elimination. They 
found that only genotype (p= 0.009) and Clcr (p=0.023) were significant predictors 
of metformin clearance. It was also shown that individuals carrying the A270S 
variant were associated with a greater metformin clearance compared with the 
reference allele. However, this study investigated the effect of only one non-
synonymous SNP (A270S) on young healthy volunteers; the situation might 
however differ in an older diabetic population. Moreover, the fact that this study 
examined one non-synonymous SNP does not exclude the effect of other 
synonymous and non-synonymous SNPs which could occur in one or more 
haplotype blocks and subsequently predict metformin clearance.  
1.19  Organic cation transporters and diabetes 
Nephropathy is a major cause of morbidity and mortality in patients with type 2 
diabetes mellitus (234, 239-240). Ethnicity has a role in the prevalence of diabetic 
nephropathy in certain regions (240). Nephropathy is defined by persistent 
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microalbuminuria (31-299 mg/l), declining glomerular filtration rate and 
hypertension (BP>135/85mmHg) (241). Structural changes in the proximal tubule 
included basement membrane thickening and glycogen accumulation (241). The 
proximal tubular transport defects may indeed occur in diabetes as suggested by 
data from investigation of the so called “protection” phenomenon seen in 
streptozotocin-diabetic rats injected with nephrotoxic agents (242-244). Grover et 
al. (241, 245) studied the association between diabetes, diabetes duration, and 
insulin treatment in the function and expression of OCT1 and 2 in the 
streptozotocin (STZ)-induced diabetes rats. They observed a decrease in both 
protein levels of OCT1 and 2 in samples obtained from rats after 14, 21, and 42 
days of diabetes compared with the non-diabetics. The results also showed that the 
expression of OCT1 was not significantly different in diabetic compared with rats 
in the non-diabetic group. On the other hand, OCT2 was significantly decreased 
within 14 days of diabetes and maximally decreased by about 50% after 21 days. 
Moreover, there was a decrease in the uptake of tetraethylammonium (TEA) in the 
STZ-induced diabetic rats compared to the control group of non-diabetic. Based on 
these results, another experiment was conducted to test whether early insulin 
treatment could prevent the observed changes in transporter expression. The results 
showed that there was no significant difference in expression of OCT1 mRNA 
among the three groups (non-diabetic, untreated diabetic, and diabetic + insulin). 
On the other hand, insulin treatment significantly attenuated the diabetes-related 
decrease in OCT2 mRNA expression. The authors of the mentioned study 
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concluded that uncontrolled diabetes caused a progressive decrease in OCT at the 
basolateral membrane.   
To date it is unknown if there is a difference in OCT expression in human kidney’s 
between controlled and uncontrolled diabetics. Thus, if OCT is less expressed in an 
uncontrolled diabetic’s kidney as it is in a rat kidney, metformin renal elimination 
will decrease and subsequently lead to increased plasma concentrations which 
might expose patients to unwanted adverse effects.  
1.20  Gender differences in the expression of OCT gene 
Urakami et al. (246) examined whether rat rOCT1 and/or rOCT2 contributed to the 
gender differences in organic cation transporter activity in the rat kidney. They 
examined accumulation of TEA by slices of kidneys from male and female rats. 
The TEA accumulation rate was approximately two fold greater in renal slices of 
male rats than female rats. In order to ascertain if there were gender differences in 
TEA transport activity of the renal basolateral membranes, TEA uptake was 
examined using isolated basolateral membrane vesicles from male and female 
kidneys. Again it was observed that TEA uptake was greater in the vesicles from 
the male kidney cortex compared to the female kidney. They also examined mRNA 
expression of rOCT1, rOCT2, and rOCT3. The amount of rOCT2 mRNA was 
much lower in females than in males and concluded that rOCT2 was responsible for 
the gender differences in renal organic cation transporter activity in the basolateral 
membrane of rat kidney. The same group further studied whether gender 
differences in rOCT2 expression was due to sex hormones or not (247). They 
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injected male and female rats with either testosterone or estradiol for 7 days. They 
then observed that administration of testosterone to male and female rats 
significantly increased in rOCT2 mRNA expression, while estradiol caused a slight, 
but not significant decrease in rOCT2 mRNA expression in males, but not in 
females. These hormone treatments had little effect on rOCT1 mRNA expression. 
They also examined the impact of hormonal treatment on organic cation transport 
activity, and reported that TEA accumulation was higher in slices from testosterone 
treated male and female rat kidneys compared to controls. However, the 
accumulation of TEA was lower in slices from estradiol treated male rats compared 
to controls. Treatment with estradiol had no significant effect on the TEA 
accumulation in slices from female rats. The expression of rOCT2 in the rat kidney 
was under strong stimulatory regulation by testosterone which had no effect on the 
expression of rOCT1 mRNA. The results of these two studies were in concordance 
with another study (248) which determined the tissue distribution of OCT 
expression in 20 tissues from male and female rats and examined whether OCT 
mRNA expression was affected by ageing. Only OCT2 mRNA levels in the kidney 
was significantly different with gender.  
To date it is unknown if there is a gender difference in OCT2 expression in the 
human kidney. If OCT2 is also differentially expressed in human kidney as in the 
rat kidney, the pharmacokinetics and subsequently, the efficacy and dispositions of 
OCT2 substrate drugs will vary between males and females.  
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In summary, metformin is considered to be an important and commonly used 
hypoglycaemic agent. It was observed that patients respond differently to metfomin 
treatment, thus inter-individual variations in the efficacy of metformin can be 
influenced by genetic factors, especially the impact of genetic variations in the drug 
transporters such as OCT1 and OCT2. Population studies have demonstrated 
significant associations between non-synonymous SNPs of OCT1 and OCT2 and 
metformin pharmacokinetics, and efficacy. Nearly all of the studies have been 
conducted on healthy individuals, very few were on diabetics usually with small 
sample sizes. However, in order to determine the effect of genetic variations of 
drug transporters on pharmacokinetics, therapeutic effects, and safety of important 
drugs such as metformin, a prospective large scale study in patients with diabetes is 
required which should be conducted in different ethnic groups from different 
genetic background. To date no genotyping studies of OCT1 and OCT2 genes have 
been conducted on the Arab population, particularly the UAE population. Thus, the 
role of OCT1 and OCT2 polymorphisms in metformin pharmacokinetic and 
efficacy is not known in this population.  
This study therefore has investigated the role of OCT1 and OCT2 genetic 
polymorphisms and studied their impact on metformin plasma concentrations in the 
UAE diabetic population.  
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2 Aims 
The main aims of this project were to: 
• Investigate factors influencing metfomin plasma concentrations. 
• Investigate the association between genetic variations in OCT1, OCT2, and 
LKB1 drug transporters and metformin plasma concentrations among a 
diabetic group of patients from the UAE population. 
• Identify the frequency of polymorphisms in OCT1, OCT2, and LKB1 genes 
among diabetic (test) and non-diabetic (control) groups from the UAE 
population. 
2.1 Research hypothesis  
• There is no significant genetic difference in polymorphisms in OCT1, OCT2, 
and LKB1 transporters between the UAE population and the Caucasian 
population.  
• There is no significant difference in metformin plasma concentrations in the 
UAE population exhibiting polymorphic patters in the OCT1, OCT2, and 
LKB1 genes. 
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2.2 Significance of the study 
In clinical practice it has been shown that patients respond variably to metformin 
treatment. Inter-individual differences in response to metformin can be due to a 
variety of factors, including age (107), renal function (105-107) , metformin dose 
(208) and genetic differences (210-211). Genetic variability in drug transporters 
involved in renal secretion, hepatic uptake, and disposition of metformin may 
explain part of the pharmacokinetic variability.  
This is the first study to investigate the impact of genetic factors on metformin 
pharmacokinetics in an Arab population, particularly the UAE population. If 
genetic polymorphisms of all candidate genes involved in metformin 
pharmacokinetics were known then it may be possible in the future to genetically 
profile patients into responders and non-responders to metformin use and that 
would be clinically relevant information for the treatment which will assist in 
establishing metformin doses especially in elderly and renal impaired patients.     
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3 Methodology 
This study was conducted at four different hospitals in the UAE, Fujairah Hospital 
and Al-Madina Medical centre, Khurfakan Hospital, Kalba Hospital, and Shaikh 
Khalifa Medical city at Abu-Dhabi UAE.  
3.1 Ethical considerations 
The research was approved by the Curtin University of Technology Human 
Research Ethics Committee Australia, the Ministry of Health, UAE, and Abu-
Dhabi Health Authority, UAE.  
Patients were required to give written informed consent in order to participate in the 
study. Data from patients were coded alphanumerically and stored on a computer 
hard disc which was password protected. Then the information that linked patients 
with their alphanumeric code was stored on a separate removable memory flash and 
kept in a secure place. That information was only available to the principle 
investigator.  
3.2 Study period 
The data collection commenced in the UAE in February 2007 and was completed 
on June 1st 2008. 
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3.3 Study personnel 
The chief investigator and the supervisor managed the study. Other staff included 
clinical pharmacists, the in-charge nurse and specialists for patient identification, 
pathology and nurses for collecting and labelling blood samples.  
3.4 Settings 
Diabetic out-patients who met the selection criteria and were visiting a diabetic 
clinic at any of the selected hospitals or health centres in the UAE during the data 
collection period were asked to volunteer for the study. 
Control non-diabetic subjects were randomly selected from different clinics at 
selected hospitals and health centres in the UAE.  
Both non-diabetic and diabetic subject were UAE citizens and were part of the local 
population. 
3.5 Subjects/Participants 
Non- diabetic (control group) 
• Not diabetic, confirmed by medical history from the medical file. 
Inclusion criteria: 
• FPG ≤ 6 mmol/L (85, 249). 
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• Out-patient. 
• Consent to participate in the study. 
• Less than 18 years old. 
Exclusion criteria:  
• On corticosteroids (increase plasma glucose level). 
• Refused to give consent for any reason. 
• They were unable to give informed consent (e.g. patients with cognitive 
dysfunction, and language barrier). 
П. Diabetic patients  
• Type 2 DM diagnosis confirmed. 
Inclusion criteria:           
• Prescribed metformin therapy for at least seven days. 
• Outpatients. 
• Consented to participate in the study. 
• Type 1 DM. 
Exclusion criteria:  
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• Women diagnosed with polycystic ovary syndrome. 
• Less than 18 years. 
• Ceased metformin treatment for any reason. 
• Refused to give consent for any reason. 
• Unable to give informed consent (e.g. patients with cognitive 
dysfunction, and language barrier). 
Subjects were withdrawn from the study if: 
• Consent was withdrawn. 
• The medical or surgical team, who was responsible for the subject’s 
care did not wish the subject to continue participation in the study. 
3.6 Data collection 
For control non-diabetic subjects, basic demographic data including age, gender, 
BMI, and ethnicity were collected. Diabetes free cases were confirmed by medical 
history through patient’s medical file and by FPG level.  
For the diabetic -test- patients, basic demographic data including metformin dose, 
medical history, BP, current medications, and duration of diabetes, smoking status, 
the level of physical activities, and demographic data (age, gender, BMI, and 
ethnicity) were collected. Patients BMI (1) were calculated using a standard 
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equation. Modification of Diet in Renal Disease Study (MDRD) equation (250-253) 
(2) was used to estimate GFR. Patients body surface area was adjusted using 
DuBois’ formula (254) (3), and the website (http://www.halls.md/body-surface-
area/refs.htm) was used to calculate body surface area. One venous fasting blood 
sample (10mL) was taken from each diabetic subject in order to determine the 
following: 
• Srcr. 
• FPG.  
• HbA1c%. 
• Plasma metformin concentration. 
• Lipid profile (LDL, HDL, total cholesterol, and triglyceride). 
• DNA genotyping. 
(1) BMI= weight (kg)/ height * height (m2) 
(2) GFR (mL/min/1.73 m2) = 186 x (Scr)-1.154 x (Age)-0.203 x (0.742 if female) x 
(1.212 if African-American) (conventional units) 
(3) Body surface area (m2) = weight (kg) 0.425 x height (cm) 0.725 x 0.007184 
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3.7 Study design 
This was a prospective cross-sectional study, diabetic patients and non-diabetic 
subjects were asked to participate in the study. The identification of non-diabetic 
subject’s for possible inclusion in the study was coordinated by the central 
laboratory consultant in all selected hospitals. While the identification for the 
diabetic patient was coordinated by specialists, and in-charge nurses in the selected 
diabetic clinic at different hospitals and health centre. 
Type 2 DM patients on long term treatment with oral metformin orally for at least 
seven days were asked to participate in the study.  
After the patient had been identified, the chief investigator met the patient and gave 
the required information of the study verbally and in written format (Appendix A). 
Before signing the consent form (Appendix B) by the patient, the chief investigator 
answered any questions related to the study. A request form was then filled in by 
the chief investigator to order a fasting blood sample, and then the co-ordinator 
nurse escorted the patients to the pathology department for a fasting blood sample. 
The chief investigator had designed a stamp labelled with “metformin study” which 
helped staff from the pathology department identify the patients who required their 
blood to be taken for the purpose of the study. The stamp was approved by the ethic 
committee in each participated hospital and a circular was distributed accordingly 
to the pathology department f. In order to observe patient confidentiality as required 
by ethics, the blood collection form did not contain the name of the patient and 
codes were used to de-identify the patients.  
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Tests for FPG, HbA1C, Scr, and lipid profile including LDL, HDL, total 
cholesterol, and triglycerides were carried out in the pathology department at each 
hospital and was performed using the equivalent machines, equipment, reagents and 
protocols approved by the UAE Ministry of Health. Samples for measuring plasma 
metformin levels were frozen at -20°C and were transported to Australia by the 
DHL express courier. In Australia, the blood samples were analysed at the 
PathCentre Laboratory at Sir Charles Gairdner Hospital. The imported samples 
complied with all international and domestic requirements concerning the safe 
handling, transport and labelling of biological material. Safety precautions were 
also maintained during shipment and handling to prevent the dissemination of 
pathogens. 
For the study purpose, renal function was classified into five groups depending on 
the degree of renal impairment (255): 
• Group one: individuals with estimated GFR > 90 mL/min/1.73m2  
• Group two: individuals with estimated GFR between 90-60 mL/min/1.73m2  
• Group three: individuals with estimated GFR < 60 and >30 mL/min/1.73m2 
• Group four: individuals with estimated GFR between 30-15 mL/min/1.73m2 
• Group five: individuals with estimated GFR < 15 mL/min/1.73m2 
Metformin plasma level was also classified into two categories (120-122, 256): 
• Category one: patients with metformin plasma levels between 0.01-1.0 mg/L 
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• Category two: patients with metformin plasma levels more than 1.0 mg/L 
Moreover, BMI was classified into four categories (257-260): 
• Category one: individuals with BMI between19.00-24.99 kg/m2 
• Category two: individuals with BMI between 25.00-30.00 kg/m2 
• Category three: individuals with BMI between 30.10-39.99 kg/m2 
• Category four: individuals with BMI ≥ 40 .00 kg/m2 
Based on the above mentioned references (257-260), individuals in the category 
two were considered overweight, and individuals in the category three were 
considered obese, while individuals in the category four were considered morbid 
obese. 
Patient’s physical activity was classified into three groups according to the level of 
physical activity (261-262): 
• Sedentary: individuals who were not involved in any kind of physical activity. 
• Irregular: individuals who were walking for less than 150 minutes per week 
• Regular: individuals who were walking for  ≥ 150 minutes per week. 
Furthermore, individuals were classified based on the duration of diabetes into three 
groups: 
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• Group one: individuals who had been diagnosed with type 2 DM between one 
week and less than 4 years 
• Group two: individuals who had been diagnosed with type 2 DM between 4 
and 10 years 
• Group three: individuals who had been diagnosed with type 2 DM for > 10 
years  
Ethnicity was sub-divided based on subjects surnames (263-264), country of birth 
(264), language spoken at home (264), and self identification information into: 
• Arabs : Individual of pure Arab origins 
• Asians: Individuals whose origins included any of the original peoples of the 
Far East, Southeast Asia, of the Indian Subcontinent, including, for 
example, India, Malaysia, Pakistan, and the Philippines.  
• Persians: Individuals whose origins were Iranian 
• Africans: Individuals whose origins were in any of the black racial groups of 
Africa 
Immediate metformin dosage form was used by all recruited patients. Metformin 
prescribed daily dose was further divided by defined daily doses (DDD) (265) into 
three groups: 
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• Group one: patients who were taking daily metformin dose between 500- < 
1900 mg/day. 
• Group two: patients who were taking daily metformin dose of 1900 and < 
2500 mg/day. 
• Group three: patients who were on daily metformin dose between 2500-3000 
mg/day. 
The DDD is a standardized dosing measure representing the recommended daily 
dose for the main indication in an adult.  
3.8 Analytical Technique for Metformin 
The blood sample analysis for determination of metformin concentrations was done 
at the Western Australian Centre for Pathology and Medical Research. 
(PathCenter). Blood samples (5ml of heparin blood in tubes not containing gel 
separator) were collected centrifuged and the plasma transferred to a second tube 
(5ml plastic). These were then stored at -200C until analysed. 
The sample preparation for analysis involved precipitation of the plasma with 
acetonitrile containing an internal standard (dihydrocodeine). The organic/aqueous 
layer was transferred to a second tube and washed with n-hexane. The hexane was 
aspirated to waste and the acetonitrile/aqueous layer taken to dryness in a water 
bath at 450C using a nitrogen stream. The residue was reconstituted in the eluting 
solvent and an aliquot injected onto the HPLC for analysis. Column used was a 
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Merk LiChrospher RP select B (5um) 250 x 4 mm Solvent was 72% acetonitrile in 
0.01M potassium dihydrogen phosphate that had previously been adjusted to pH 
8.0 with diethylamine. Flow rate = 1.5 ml/min. Detector wavelength was 235nm.  
The venous lactate levels were determined by an enzymatic method with standard 
automated techniques. 
3.9 Genotyping 
Initially the LKB1 gene was not included in the study methodology; however, after 
understanding the upstream regulators of OCT genes, and the postulated 
mechanism of action of metformin, the decision was made to include the LKB1 in 
the genetic screening and analysis of the studied population. In this study, all 
exonic and flanking intronic regions of OCT1, OCT2, and LKB1 were screened and 
compared with the observed SNPs in this population with the reported SNPs in 
other populations.  
As mentioned previously, in the human the genes coding for OCT1 and OCT2 are 
localized within a cluster on chromosome 6q26 (228-230), and each of the two 
genes comprises 11 exons and 10 introns (229, 231, 266). The Human LKB1 is 
located on chromosome 13.3p19, and comprises 10 exons (266). The forward and 
reverse primers were designed based on the flanking intronic region to amplify the 
full exon sequences. The sequence data were fitted by the DNAMAN sequence 
alignment software and compared against the NCBI reference sequences to 
investigate for genetic variations. The genotypes were confirmed by two 
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independent observers. In order to compare the genotypes of the UAE populations 
with the reported SNPs in other populations, SNP data of OCT1 and OCT2 genes 
from the Genome Variation Server database version 5.09 (267)  were downloaded.  
3.9.1 Genomic DNA extraction 
Blood samples from control non-diabetic individuals and diabetic patients were 
collected in K3EDTA BD Vacutainer® Blood Collection Tubes (1 Becton Drive, 
Franklin Lakes, NJ USA). The samples were frozen at -200C until they were ready 
for processing.  
Protocol: The stored blood samples were used for DNA isolation. 
1. Approximately 500 µl of blood samples were added to 500 µl of digestion 
buffer containing proteinase K and incubated overnight at 650C for protein 
digestion for 1 hour in a water bath.  
2. After incubation the mixture was heated to 850C for 10 minutes to 
inactivate proteinase K.  
3. The suspension was centrifuged at 10,000 revolutions per minute (rpm) for 
3 minutes to collect the supernatant.  
4. The supernatant was then transferred to a new tube and an equal volume of 
phenol was added directly & mixed gently.  
5. The above mixture was centrifuged at 12,000 gravity (g) for 7 minutes at 
40C.  
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6. The aqueous layer was taken out carefully in an Eppendorf® tube and an 
equal volume of phenol: chloroform: isoamyl alcohol (25: 24: 1) was 
added.  
7. The above aqueous mixture was centrifuged at 12,000 g for 10 minutes at 
40C. 
8. The aqueous layer was separated and chloroform: isoamyl alcohol (24: 1) 
was added and centrifuged at 12,000 g for 10 minutes at 40C. 
9. The aqueous layer was separated and DNA was precipitated by adding 
twice the volume of chilled 100% ethanol and 1/10th volume of 3 M 
sodium acetate (pH 5.2), by incubating it in a -200C freezer overnight.  
10. The precipitate was pelletted by centrifugation at 10,000 rpm for 10 
minutes, and washed twice with 70% ethanol and air-dried.  
11. 50 µl of 1 X TE buffer (pH 8) was used for dissolving the stored DNA for 
later use.  
12. DNA concentration and purity of samples was measured with a Nanodrop 
1000 (ThermoFisher Scientific, USA) and run on 0.8% agarose gel for 
quality assessment. 
3.9.2 Polymerase Chain Reaction 
In this study, PCR was used to amplify the specific exons. Specific primers were 
designed using Primer3 software (268)  to amplify the entire exonic region and the 
specificity of the primers were confirmed by UCSC in silico PCR Genome Browser 
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website (269). The primers were ordered from Metabion International AG and the 
sequences of all primers and the annealing temperatures used are given in Table 13.  
1. 1 μl of 10-50 ng of genomic DNA were aliquoted into 96 well plates.  
2. PCR master mixes were prepared for the specific primers in excess to 
correct for pipetting errors. 
3. The master mix comprised of 0.2 5 μM o f each p rimer; 1 0 mM Tris-HCl 
pH 8.0, 1.5 mM MgCl2, 50 mM KCl, 1 unit of GoTaq Hot Start 
Polymerase (Promega, USA), 200 μM of each dNTP. 
4. PCR was performed on a final volume of 25 μL using a Thermal Cycler 
9700 (Applied Biosystems, Foster City, CA, USA).  
5. The thermocycling protocol consisted of an initial incubation at 95°C for 
10 minutes followed by 35 cycles at 94°C for 30 seconds; 30 seconds at 
annealing temperature for each primer (Table 13) and elongation at 72°C, 
and a final extension step of 72°C for 10 minutes.  
6. The amplified DNA fragments were subjected to electrophoresis on a 2% 
agarose gel containing ethidium bromide, and then visualized under UV 
light.  
3.9.3 Sequencing 
Protocol: The PCR products were transferred to optical plates (Applied 
Biosystems, USA) and sequenced using both forward and reverse primers. Prior to 
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sequencing, to dephosphorylate any residual amplification nucleotides and the 
unused primers, the PCR products were purified with Shrimp Alkaline Phosphatase 
in combination with Exonuclease I.  
1. 2 μL of the PCR products were purified with 0.5 U Shrimp Alkaline 
Phosphatase (SAP) (USB Corporation, USA) in combination with 5 U of 
Exonuclease I (ExoI) (USB Corporation, USA).  
2. The above mixture was incubated at 37°C for 30 minutes, followed by 15 minutes 
at 85 °C to inactivate the enzyme (performed in a Thermal Cycler).  
3. 5 μL of the purified PCR products were sequenced with BigDye® Terminator 
v3.1 Cycle Sequencing Kit (Applied Biosystems, USA) in both directions with the 
same primers as used for PCR.  
4. The cycling conditions were as follows; 
• 960C for one minute, followed by 25 cycles of 960C for 10 seconds, then 
500C for 5 seconds, and finally 600C for 4 minutes. 
5. Sequencing reactions were cleaned using the ethanol/EDTA/sodium Acetate 
precipitation method following the instructions provided by the BigDye® 
Terminator v3.1 Kit. 
6. The precipitated cleansed sequencing reaction products were kept in the dark and 
then air dried. 
7. Samples were re-suspended in 15 μL Hi-Di™ formamide (Applied Biosystems, 
USA) and run in an ABI3730 DNA Analyser (Applied Biosystems, USA). 
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3.10  SNPs discovery and Statistical analysis 
Sequencing data were collected through an ABI3730 DNA Analyser and analysed 
by Sequencing Analysis Software Version 5.1 (Applied Biosystems, USA) using 
mixed base identification. Multiple sequence alignment was performed using 
DNAMAN sequence analysis software (Lynnon Biosoft, Canada). The suspected 
SNPs detected in DNAMAN multiple nucleotide sequence alignments were 
confirmed by observation of the electropherogram in SeqScape (Applied 
Biosystems, USA). The intron/exon and protein coding region of genes were 
compared with gene sequences in the NCBI database. GENEPOP software 
Statistical analysis was carried out using GENEPOP (270). Minor allele frequency 
(MAF) and Hardy Weinberg Equilibrium (HWE) and FIS was analysed using the 
standard options available in the program. The Genome Variation Server version 
5.09 (GVS) was used to compare the distribution of minor allele frequencies and 
heterozygosity in the European (CEU), Japanese (JPT), Chinese (CHB) and the 
African (YRI) populations (267).   
3.11  Statistical analysis 
3.11.1 Sample size estimation  
Based on the analysis of two articles (120, 256), the mean values for metformin 
plasma levels and their standard deviations for different levels of renal dysfunction 
are shown in Table 9.  
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Table 9: The mean plasma metformin concentrations and their corresponding creatinine 
clearance 
Clcr (mL/min) Metformin level (mg/L) (mean ± 
standard deviation (SD) 
Group 1 (<10) 42.1 ± 26.3 
Group 2 (11-20) 7.6   ±7.3 
Group  3 (21-30) 3.3   ± 2.9 
Group 4  ( > 30 ) 1.6   ±1.6 
 
Based on the above data, a sample size of 239 patients will initially be selected as it 
is sufficient to detect a difference of 20% in metformin level with over 80% power 
if the standard deviation was 50% of the mean or less. 
Data were analysed using SPSS® software version 17 for Windows. Metformin 
plasma concentration was considered as the dependent variable. Age, gender, 
height, ideal body weight, BMI, metformin dose and GFR were considered as 
independent variables. The Chi-square test was used to detect any significant 
differences between metformin plasma concentration and other variables. Logistic 
regression was used to test the independent association between metformin plasma 
concentration and associated factors of interest including age, gender, BMI, 
metformin dose, HbA1c, and OCT1 and OCT2 and LKB1 polymorphisms. 
Correlation studies were done using Pearson’s correlation. A p value of < 0.05 was 
considered to be statistically significant. Data were presented as mean ± standard 
error (SE) unless otherwise stated. All metformin levels measured were trough 
concentration at steady state. For the purpose of the current study, concentrations of 
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0.01 to 1.0 mg/L were considered as a therapeutic reference range for metformin 
plasma levels (120-122). Any concentration above that was considered to favour 
the accumulation of metformin.  
 
 
85 
 
4 Results 
A total of 461 eligible diabetic subjects and 185 control non-diabetic subjects were 
identified in all the study hospitals in the UAE.  
Of the 461 diabetic subjects, 374 were approached by the investigator (81.1%). Of 
the 374 subjects, 323 volunteered to participate in the study (86.4%) of which 31 
were excluded for different reasons, the remaining 292 patients had a blood sample 
taken and analyzed in the study as demonstrated in Figure 7. While out of 196 
identified non-diabetic individuals, only 170 approved to participate in the study 
and had a blood sample taken for FPG, HbA1c, and DNA analysis.   
4.1 Demographics of diabetic subjects 
From 292 patients 64% were females. The  mean age for this group of patients were  
54 ±0.7 years (Table 10).  
4.2 Demographics of control non-diabetic subjects 
From 170 control non-diabetic subjects 60% were females, the mean age at 
recruitment was 49 ±0.84 years. Table 10 illustrates the demographic data of the 
recruited diabetic and control subjects.  
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Figure 7: Illustrations of the result of patient’s recruitment 
9 medically not suitable 
(As determined by the 
treating clinician) 
323 signed to participate in 
the study and had a blood 
sample requested 
292 had a useable blood 
sample  
8 did not had their blood 
sample taken because the 
patients were not fasting 
16 samples were 
misplaced 
461 diabetic patients on metformin identified 
7 samples were too small for 
analysis 
42 refused to 
participate in the study 
374 approached by investigator 
 
87 left the clinic before being 
approached by investigator 
 
19 had zero metformin 
plasma concentrations 
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Table 10: Clinical parameters and demographic data of diabetic UAE patients (n= 292) and 
control subjects (n= 170) recruited in the study. Results are mean ±SE 
Demographic/clinical 
parameters 
  P value  
 Diabetic (test) Non-diabetic 
(control) 
 
Sample number (n) 292 170  
Female (n, %) 187 (64%) 102 (60%) 0.076 
Male (n, %) 105 (36%) 68 (40%) 0.076 
Age (Years) 54.00 ± 0.7 49.00 ± 0.8 0.002 
BMI (Kg/m2) 30.36 ± 0.35 30.46 ± 0.31 0.314 
FPG (mmol/L) 9.26 ± 0.21 4.63 ± 0.04 < 0.0001 
 HbA1c% 8.15 ± 0.12 4.50 ± 0.04 < 0.0001 
Cholesterol (mmol/L) 4.70 ± 0.19 NA* NA 
Triglyceride (mmol/L) 1.82 ± 0.06 NA NA 
 LDH (mmol/L) 2.65 ± 0 .06 NA NA 
 HDL (mmol/L) 1.40 ± 0.02 NA NA 
GFR (mL/min/1.73m2) 88 ± 1.6 NA NA 
Metformin concentration 
(mg/L) ‡ 
0.62 ± 0.03 NA NA 
Metformin dose (mg/day) 1622 ± 28 NA NA 
*NA: not applicable 
‡ The mean value for this parameter was based on 273 patients; subjects with zero metformin 
plasma concentrations were excluded 
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4.3 Metformin plasma concentrations  
The mean metformin plasma concentration for the 273 diabetic groups of patients 
was 0.62 ±0.03 mg/L with a minimum of 0.01 and a maximum of 4.28 mg/L, of 
which 83% had metformin plasma concentrations between 0.01-1.0 mg/L. Nineteen 
patients recorded zero metformin level, and they were excluded from further 
regression analysis because they were considered non compliant to therapy. Thus, 
any analysis between the investigated variables and metformin plasma 
concentrations included 273 patients, excluding those clearly non-complaint. 
However, demographic, biochemical and genetic baseline data were estimated on 
the total of 292 diabetic patients.   
4.4 Association between metformin plasma concentration with 
demographic variables and clinical parameters in the diabetic 
group 
As stated in the methodology section, each variable was categorized into different 
groups, and then a cross tab chi-square test was used to investigate the possible 
association between those variables and metformin plasma concentrations in the 
273 diabetic patients. If an association was established by a significant p value (< 
0.05) then further multiple regression was performed on independent significant 
variables.  
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4.4.1 Patient’s age 
The mean age of the 292 diabetic patients who were prescribed metformin therapy 
was 54.00 ±0.7 years with a minimum of 19 years and a maximum of 100 years 
old. There were 53 patients aged ≥65 years (18%) with mean GFR of 21.2 
mL/min/1.73m2. Of the recruited patients 82% were in the age group between 46-
64 years.  
The result of the study showed that there was no significant association between 
patients age and metformin plasma concentration (p= 0.15), thus patient age was 
not included into further analysis.  
4.4.2 Patient’s gender 
It was shown that 64% of the recruited diabetic population was female. Of the 273 
diabetic patients, 11% of the females had metformin plasma concentration more 
than 1.0 mg/L, while 5% of the males had metformin plasma concentration more 
than 1.0 mg/L.  
It was found that there was no significant association between patient’s gender and 
metformin plasma level (p= 0.33), thus gender was not included in further 
regression analysis in this study.  
4.4.3 Patient’s BMI  
The mean BMI for the recruited 292 diabetic patients was 30.36 ±0.35 kg/m2, with 
a minimum of 19.00 and maximum of 56.00 kg/m2. It was found that 76% of the 
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patients were overweight or obese. There was a significant difference between 
males and females in BMI measures (p= 0.001), the female population was more 
obese than the male population.  
The results showed no significant association between BMI and metformin plasma 
concentration (p= 0.13). Although there was a significant difference between males 
and females in BMI, however, the results showed that there was no significant 
association between the average male BMI and average female BMI and metformin 
plasma concentration (p= 0.14 and p= 0.47 respectively). Therefore, BMI was not 
included in any further analysis.  
 
4.4.4 Patient’s ethnicity 
Of the 292 recruited populations, a majority were of Arab origin (74.7%), (Figure 
8); with 15% of the Arab population having a metformin plasma concentration 
more than 1.0 mg/L, (Table 11).  
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Figure 8: Representation of different ethnic groups in the diabetic population of the UAE, n= 
292 
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Table 11: Ethnicity Vs metformin plasma concentration (mg/L)  p = 0.71, n= 273 
 Metformin category Total 
0.01-1.0 (mg/L) > 1.0 mg/L 
Ethnicity Arab Number (%) 173 (85%) 31 (15%) 204 
Asian Number (%) 23 (77%) 7 (23%) 30 
Persian Number (%) 20 (83%) 4 (17%) 24 
African Number (%) 13 (87%) 2(13%) 15 
Total 229 44 273 
 
The results demonstrated that all ethnic groups had poor glycemic control 
(HbA1c=8.15 ±0.12%); however 93% of African origin recorded higher HbA1c 
level compared to 69% Arabs and 83% in both Asian and Iranian ethnic groups.  
Patients ethnicity was not significantly associated with metformin plasma 
concentration (p= 0.71). With the exception of Arab ethnicity that would be 
included in sub-analysis with any observed significant variables with metformin 
plasma concentrations; patient ethnicity was not included in further analysis. 
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4.4.5 Patient’s physical activity  
Of the recruited 292 patients 52% led a sedentary lifestyle, with the remaining 37% 
and 11% involved in irregular and regular physical activity groups respectively. 
There were no significant differences between males and females in the level of 
physical activity.  
The results showed that there was no significant association between patients 
physical activity and metformin plasma concentration (p= 0.29), therefore, patients 
physical activity was not included in further analysis.   
4.4.6 Duration of diabetes 
According to the methodology used in this study, patients were classified into 
different categories based on the duration of diagnosed diabetes. They ranged from 
being diagnosed from one week to more than 30 years. Patients were distributed 
almost evenly in each group, and most of them had metformin plasma levels 
between 0.01 to 1.0 mg/L, thus, the results showed that of the 273 diabetic patients 
there was no significant association between the duration of type 2 DM and 
metformin plasma level (p= 0.11).  
4.4.7 HbA1c  
The mean HbA1c for the recruited 292 patients was 8.15 ±0.12%, with a maximum 
of 15.3% and a minimum of 3.3%. The results revealed that the HbA1c variation 
between males and females didn’t reach statistical significance (p= 0.055). 
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The results also showed that in the 273 patients there was no significant association 
between glycemic control measured by HbA1c level and metformin plasma 
concentration (p= 0.65), thus HbA1c was not included in further regression 
analyses.  
4.4.8 Lipid profile  
Triglycerides: Mean triglyceride was 1.82 ±0.06 mmol/L. No significant 
association was observed between triglyceride levels and metformin plasma 
concentration (p= 0.09).  
LDL: Mean LDL level was 2.65 ±0.06 mmol/L. There was no significant 
association between LDL plasma level and metformin plasma level among patients 
(p= 0.13).  
Cholesterol: Mean cholesterol level was 4.70 ±0.19 mmol/L. There was no 
significant association between cholesterol level and metformin plasma 
concentration (p= 0.97). 
HDL: Mean HDL level was 1.40 ±0.02 mmo/L. There was no significant 
association between HDL level and metformin plasma concentration within the 273 
diabetic patients (p= 0.20). Therefore, lipid profiles were not included in further 
regression analyses with metformin plasma concentration.  
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4.4.9 Metformin dose 
The mean metformin dose in the 273 diabetic patients with measured metformin 
plasma concentrations, was 1622 ±28 mg/day, with a minimum of 500 and a 
maximum of 2550 mg/day. According to the methodology followed in this study, 
metformin daily dose was classified into three groups. The result of this study 
showed that metformin dose was significantly associated with metformin plasma 
level (p= 0.012). Patients with higher metformin doses had recorded higher 
metformin plasma levels. Thus, metformin dose was included in the regression 
analyses.   
4.4.10 GFR 
The mean GFR using MDRD formula (250-253) was 88 ±1.6 mL/min/1.73m2 with 
a minimum of 17 and maximum of 229 mL/min/1.73m2.  
The results showed a highly significant association between patients GFR and 
patients age (p< 0.0001) (Table 12), it also revealed a significant association 
between GFR and metformin plasma concentration (p= 0.001), thus, GFR was 
considered for further regression analysis with metformin plasma concentration.  
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Table 12: The association between patient’s age category and GFR group, n= 292  
GFR mL/min/1.73m2 Age (years) 
 18-30 31-46 47-64 ≥65 
> 90 5% 31% 57% 7% 
90-60 1% 16% 61% 22% 
< 60-15 0% 1% 51% 48% 
 
4.5 Complications of diabetes, CVD 
Almost 33% of the recruited patients were diagnosed with CVD (MI, angina, and 
CHF) of this group 10% had metformin plasma concentrations above 1.0 mg/L (p= 
0.002), and 78% were diagnosed with hypertension and were on different groups of 
antihypertensive medications. Moreover, 74% of the diabetic patients were on statin 
antihyperlipidemia treatment. Of the diabetic and hypertensive patients 39% were 
diagnosed with CVD and were on medications prescribed to control this 
complication, hence, there was a significant association between hypertension and 
CVD (p< 0.0001). Of all the diabetic patients 7% were smokers and 26% of them 
quit smoking either recently, 6 weeks or as long as 20 years earlier. Of the 7% 
smokers, 38% were diagnosed with CVD, thus, there was a significant association 
between smoking status and the presence of CVD in the diabetic patients (p< 
0.0001). Furtheremore, 26.5% of the diabetic patients who were diagnosed with 
CVD had HbA1c> 7% (p= 0.002). Figure 9 summarizes the effect of different 
variables on the presence of CVD in the diabetic patients.  
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The result of this study showed that out of 292 diabetic subjects, 45 patients were 
on metformin therapy mono-therapy, the remaining 247 patients were prescribed 
combinations of metformin with other hypoglycaemic agents, Table 13.  
 
Table 13: Combination of metformin therapy with other oral hypoglycaemic agents 
represented with number of patients in each combined regimen, n= 247 
Combined therapy Number of patients (n) 
Metformin plus sulphonylureas 166 
Metformin plus rosiglitazone 17 
Metformin plus insulin and 
sulphonylureas 
28 
Metformin plus insulin 27 
Metformin plus sulphonylureas and 
rosiglitazone 
9 
 
There was no significant association between treatment regimen as mono and 
multi-hypoglycaemic therapy (p= 0.52), however, there was a significant 
association between the duration of the disease and treatment regimen as mono-
therapy with metformin and multi-therapy with other hypoglycaemic agents (p< 
0.0001); as an increase in the duration of the disease led to a poor glycemic control 
and subsequently addition of other hypoglycaemic agents into the treatment 
regimen.     
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Figure 9: The percentage of CVD in the diabetic population and the percentage of other 
variables and the association between these variables with the presence of CVD represented 
by p value. 
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78%      
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292 diabetic 
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P< 0.0001 P< 0.0001 
p= 0.002 
p= 0.002 
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In summary, among all demographic and clinical data that were collected and 
analysed; within the diabetic patients, metformin dose and GFR showed a 
significant association with metformin plasma concentrations, hence were included 
in the multiple regression analysis.    
4.6 Genotypes 
The genotyped alleles for the candidate genes were categorized into homozygotes 
(both alleles are the same) and heterozygotes allele (both alleles are different). The 
reported allelic variations (polymorphism) were classified into synonymous and 
non-synonymous polymorphism based on the NCBI SNP reference 
(http://www.ncbi.nlm.nih.gov/). Genotype was carried on all of the UAE 
population, including diabetic and non-diabetic groups. However, in order to 
investigate the association between metformin plasma concentrations and genetic 
polymorphisms of the candidate genes, only the diabetic group was considered in 
the analysis. Genetic variations were categorized into two group homozygotes and 
heterozygotes. A cross tab chi-square test was used to investigate the possible 
association between genetic variation and metformin plasma concentrations in the 
273 diabetic patients. If an association was established by a significant p value (p< 
0.05) then further multiple regressions was carried on independent significant 
SNPs.  
Table 14 shows the list of primers used in the study along with the sequences, 
annealing temperatures and expected product size.  
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4.6.1 OCT1 (SLC22A1) 
The results of the study showed that of the reported 28 SNPs in the NCBI data base 
12 were polymorphic in the UAE population. Table 15 illustrates the details of the 
SNPs, exonic location, functional consequence of amino acid change, and the 
percentage of MAF reported in the study population. Among the reported 
polymorphic SNPs in the OCT1; 9 were with MAF> 0.01%. No novel SNPs were 
found in any of the OCT1 exons. MAF of the observed SNPs in the UAE 
population were not always matching with those reported in Caucasians, although it 
was sometimes comparable with other ethnic populations, such as African or Asian. 
Table 16 demonstrates a summary of the polymorphism observed in the OCT1 gene 
among the UAE population in comparison with the other major population groups 
in the GVS database.  
4.6.2 OCT2 (SLC22A2) 
It was observed that of the 18 reported SNPs in the database, five were found to be 
polymorphic in this population, of which three were with MAF> 0.1%. Table 17 
shows genotyped polymorphisms in the OCT2 gene along with their exonic 
location, NCBI SNP reference ID, functional consequence of amino acid change 
and MAF observed in the UAE population. A novel synonymous Ser 279 (A/G) 
variation was found in exon one not reported in any other population, with an MAF 
1.03%. The electropherogram for this SNP is shown in Figure 10. Moreover, the 
majority of the reported SNPs in this population were comparable with Caucasians. 
Furthermore, some of the observed SNPs in the study population were also reported 
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in the Caucasian population but with different MAF. Table 18 demonstrates the 
summary of polymorphisms with MAF> 0.1% observed in the OCT2 gene among 
the UAE population in comparison with the other major populations in the GVS 
database.  
4.6.3 LKB1 
The genotype results of the LKB1 gene showed of four reported SNPs in the 
database, two polymorphisms were found in the UAE population; the non-
synonymous 125Ile>Thr (rs11552325) and synonymous Tyr (rs9282859) SNPs 
with MAF= 0.01%.  Table 19 discloses genotyped polymorphisms in the LKB1 
gene along with their exonic respective location, NCBI SNP reference ID, 
functional consequence of amino acid change and MAF observed in the UAE 
population. 
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Table 14: List of primers used in the study along with the sequences, annealing temperatures and expected product size. 
Gene Exon  
Primer sequence Forward 
(5´-3´) 
Reverse (5´-3´) Annealing  
Temperature (°C) 
Product size  
(bP) 
OCT1 1 cttggttgccttccagatgt tcccaggaactcccatgtta 57 590 
 2 cctcttgccgtggtatgact tccagcagcttctgcagtta 57 250 
 3 atttcaacctctcccacctg ccatcccattctaccctgag 57 248 
 4 gggaaggagaaatgggagac cgttatgcatgtggacacca 60 495 
 5&6 ccgaggaaaatgccagatag ctggagagacgcacaggaac 57 499 
 7 gggcccttctaggacactct cctcatctttgttctcattcca 55 492 
 8 caccatggcctctcacagta gggttcacagccatttcact 55 231 
 9 tcctcatggttcctcctgac cgagctgcaaaagaaggaat 55 323 
 10 ttggctggctgtgattatttc  tgatattaggccccttttgg 55 249 
 11 ttgcaacagttccatcatcaa  agcaccaacagctttcccta 55 385 
      
OCT2 1 tttgggaagtgcaggaaggac ccthcttgcttccttgagaa 55 698 
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 2 agggcaagccttttggttat gaaaggatgggattcaagca 55 578 
 3 cagtctgtgcctcctggatt gaagctgggtcccttttctt 55 391 
 4 ctgctaagttaccaagccattt cccaaagagaaaggacatttg 55 850 
 5 atccagtccttgacccctct gaagctcctcacgtgacctt 55 697 
 6 ctagtgctgggcatgagatg atttgcccaagaaaaacacg 60 392 
 7 cacagccagccactgaagta gctggccatatgaatttgct 55 554 
 8 catgagcctatagaagaagtcatt tcacgttattttcaatgcacaa 55 693 
 9 caattgctcctcccatcatt acatccaggaagaacgcaag 55 660 
 10 tggtggcaatgtcctctacc gaccttctccacgtgaaagttta 55 574 
 11 ttctttctcccctctccattt ttttaaaatccacaaatgttaagaca 60 836 
      
LKB1 1 ggccgtgttcatacttgtcc cgctaccagggcattttaac 58 966 
 2 gttgggctctccaggtgtg gaaccatcagcaccgtgac 60 394 
 3 ccaagagtcagccctgtcc aacttgggccttcatgtcaa 58 431 
 4&5 gtgtgcctggacttctgtga accaccatctgccgtatgag 58 650 
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 6 ctaccccgtagcctccacta cagtcctctcaatgcctgct 60 425 
 7 ccttaggagcgtccaggtatc cctcactcagaccccagttc 60 400 
 8 tcctgagtgtgtggcaggta gaagctgtccttgttgcaga 62 387 
 9 tgcctcctactcgtgaggtt cgactcagcctcagccatac 60 996 
 10 acctcttccgtcttccttcc gttgagacgcgaacaaaacc 55 900 
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Table 15: Summary of genetic variations detected in the OCT1 (SLC22A1) gene with minor 
allele frequencies (MAF) in the UAE population, n= 462 
No  Location NCBI SNP ID Functional 
Consequence 
Allele 
change 
mRNA 
position 
MAF 
(%) 
1 Exon 1 rs35888596  Non-synonymous A/G 218 3.3 
2 Exon 1 rs1867351  synonymous C/T 261 28 
3 Exon 1 rs12208357  Non-synonymous C/T 286 4.3 
4 Exon 1 rs55918055  Non-synonymous C/T 367 0.4 
5 Exon 2 rs683369  Non-synonymous C/G 585 11.2 
6 Exon 3 rs34134157  synonymous C /T 663 0.2 
7 Exon 6 rs2282143  Non-synonymous C/T 1127 3.4 
8 Exon 7 rs628031  Non-synonymous A/G 1327 6.3 
9 Exon 7 rs34888879  synonymous A/G 1344 0.3 
10 Exon 9 rs35270274  Non-synonymous G/T 1568 4.1 
11 Exon 10 rs41267797  synonymous A/G 1608 3.3 
 12 Exon 11 rs16891138  synonymous A/C 1752 1.3 
* Highlighted data indicates the SNPs of MAF≤ 0.01 
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Table 16: Summary of genetic variation observed in OCT1 (SLC22A1) gene among the 
UAE population in comparison with the other major populations reported in the genome 
variation server (GVS) database 
Location NCBI SNP ID CEU* JPT* HCB* YRB* UAE 
Exon 1 rs1867351  
 Alleles C/T C/T C/T C/T C/T 
 Minor allele, MAF 
(%) 
C (21) C (45) C (44) C (29) C(28) 
 Heterozygosity 0.33 0.50 0.49 0.41 0.3 
 Hardy-Weinberg 
chi-Square 
0.15 0.06 0.05 0.42 0.73 
Exon 2 rs683369  
 Alleles G/C G/C G/C G/C G/C 
 Minor allele, MAF 
(%) 
G (20) G (10) G (13) 1 G (11.2) 
 Heterozygosity 0.37 0.18 0.22 0.03 0.198 
 Hardy-Weinberg 
chi-Square 
2.16 1.87 2.68 0.02 0.84 
Exon 6 rs2282143      
 Alleles C T/C T/C T/C T/C 
 Minor allele, MAF 
(%) 
mono T (12) T(11) 8 T (3.4) 
 Heterozygosity mono 0.21 0.19 0.14 0.06 
 Hardy-Weinberg 
chi-Square 
NA 0.00 6.77 0.71 0.079 
Exon 7 rs628031  
 Alleles A/G A/G A/G A/G A/G 
 Minor allele, MAF 
(%) 
A (44) A (17) A (22) A (24) A (6.4) 
 Heterozygosity 0.49 0.29 0.34 0.37 0.119 
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 Hardy-Weinberg 
chi-Square 
0.97 1.25 11.72 0.06 1.45 
Exon 11 rs16891138  
 Alleles A A A C/A C/A 
 Minor allele, MAF 
(%) 
mono mono mono C (6) C (1.3) 
 Heterozygosity mono mono mono 0.11 0.025 
 Hardy-Weinberg 
chi-Square 
N/A N/A N/A 0.42 0.67 
MAF is the fraction of total alleles of the given marker that are minor alleles; mono = 
monomorphic SNP, NA not applicable. GENEPOP software was used to estimate MAF and 
Hardy-Weinberg chi-Square. 
* CEU: Europeans, JPT: Japanese, HCB: Chinese, and YRB: Africans. 
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Table 17: Summary of genetic variations detected in the OCT2 (SLC22A2) gene with MAF 
in the UAE population, n= 462 
No Location NCBI SNP 
ID 
Functional 
Consequence 
Allele 
change 
mRNA 
position 
MAF (%) 
1 Exon 1 rs624249  synonymous G/T 560 33.4 
2 Exon 4 rs316019  Non-synonymous G/T 978 10.4 
3 Exon 6 rs45599131  Non-synonymous T/G 1222 1.0 
4 Exon 8 rs3907239  Non-synonymous A/G 1558 1.0 
5 Exon 10 rs316003  synonymous C/T 1676 12.2 
 *Highlighted data indicates the SNPs of MAF≤ 0.01 
 
 
 
Figure 10 : Electropherogram of novel synonymous Ser 279 (TCTCAGCTA) SNP in exon1 
of OCT2 (SLC22A2) gene that was found in the UAE population. 
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Table 18: Summary of genetic variation observed in OCT2 (SLC22A2) gene among the 
UAE population in comparison with other major populations reported in the genome 
variation server (GVS) database 
Location NCBI SNP ID CEU JPT HCB YRB UAE 
Exon 1 rs624249  
 Alleles A/C A/C A/C A/C A/C 
 Minor allele, 
MAF (%) 
A (40) A(20) A (17) A(24) A (33.4) 
 Heterozygosity 0.48 0.32 0.28 0.36 0.44 
 Hardy-Weinberg 
chi-Square 
0.03 0.14 0.23 0.03 0.46 
Exon 4 rs316019  
 Alleles A/C A/C A/C A/C A/C 
 Minor allele, 
MAF (%) 
A(10) A(12) A(11) A(16) A(10.3) 
 Heterozygosity 0.18 0.20 0.20 0.27 0.184 
 Hardy-Weinberg 
chi-Square 
0.02 0.00 0.00 0.00 0.00 
Exon 7 rs8177516  
 Alleles G G G A/G G 
 Minor allele, 
MAF (%) 
mono mono mono T (1) mono 
 Heterozygosity mono mono mono 0.02 mono 
 Hardy-Weinberg 
chi-Square 
NA NA NA 0.00 NA 
Exon 8 rs8177517      
 Alleles T T T G/T T 
 Minor allele, 
MAF (%) 
mono mono mono G (6) mono 
 Heterozygosity mono mono mono 0.11 mono 
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 Hardy-Weinberg 
chi-Square 
NA NA NA 0.23 NA 
Exon 10 rs316003  
 Alleles C/T C/T C/T T/C C/T 
 Minor allele, 
MAF (%) 
C (19) C (14) C (19) T(46) C (12.2) 
 Heterozygosity 0.31 0.24 0.31 0.50 0.214 
 Hardy-Weinberg 
chi-Square 
0.44 0.05 0.15 0.53 1.42 
 
 
 
 
 
 
 
Table 19: Genotyped polymorphisms in LKB1 gene along with their exonic location, NCBI 
SNP reference id, functional consequence of amino acid change and Minor Allele 
Frequencies (MAF) in the diabetic patients, n= 462 
Gene  Location NCBI SNP ID Functional 
Consequence 
Allele 
change 
mRNA 
position 
MAF 
(%) 
LKB1       
 Exon 1 rs56354945  synonymous A/C 1379 mono 
 Exon 2 rs11552325  Non-
synonymous 
C/T 1489 1.0 
 Exon 6 rs9282859  synonymous C/T 1931 1.0 
  Exon 8 rs59912467  Non-
synonymous 
G/C 2177 mono 
MAF = Minor Allele Frequency (%), mono = monomorphic, p value < 0.05 was considered 
significant. 
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4.7 Association between metformin plasma level and OCT1 
variations 
Among all of the 9 SNPs reported in the study population only two were found to 
be significantly associated with metformin plasma concentration, OCT1-E1 
synonymous Ser SNP (rs1867351), and OCT1-E9 non-synonymous 488Arg>Met 
SNP (rs35270274) with p= 0.001 for both variables. It was also observed that 33% 
of the diabetic patients were carrying OCT1-E1 synonymous Ser SNP (rs1867351) 
variants of which 27% had metformin plasma concentration above 1.0 mg/L. 
While 5% of the patients had polymorphism in OCT1-E9 non-synonymous 
488Arg>Met (rs35270274) of them 53% recorded metformin plasma concentration 
above 1.0 mg/L. Table 20 illustrates OCT1 variations along with the percentage of 
heterozygocity in association with the percentage of metformin plasma 
concentration that was above 1.0 mg/L and the p value of the association of those 
reported SNPs with metformin plasma concentration.  
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Table 20: demonstrates OCT1 genetic variations and the percentage of the OCT1 
heterozygocity reported in the diabetic patients. It also shows the percentage of the patients 
with the polymorphic alleles in the higher metformin plasma concentration category (above 
1.0 mg/L). 
OCT1 variation % Heterozygocity % of polymorphic 
patients with 
metformin level 
>1.0 mg/L 
p value 
E1 23Leu>Val 
rs34570655 
<1 0 1 
E1 38Gly>Asp 
rs35888596 
4 9 0.81 
E1 Ser          rs1867351 33 27 0.001 
E1 61Arg>Cys              rs 
12208357 
33 15 0.87 
E1 88Cys>Arg 
rs55918055 
<1 0 1 
E2 160Leu>Phe             
rs 683369 
17 13 0.49 
E3 Asn       rs34134157 <1 0 1 
E6 341Pro>Leu 
rs2282143 
8 7 0.57 
E7 408Met>Val 
rs628031 
6 29 0.30 
E7 Ala      rs34888879 <1 0 1 
E9 488Arg>Met 
rs35270274 
5 53 0.001 
E10 Val    rs41267797 12 9 0.27 
E11 Ser     rs16891138 3 2 0.85 
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4.8 Association between metformin plasma level and OCT2 
variations 
The OCT2 gene was less variant than OCT1 gene, the results of the study revealed 
that OCT2 genetic variations were not significantly associated with the metformin 
plasma concentration as indicated by p value. Table 21 demonstrates OCT2 exonic 
variations with the percentage of heterozygocity, percentage of patients with 
polymorphism that had metformin plasma concentration above 1.0 mg/L, and the p 
value for each of the OCT2 reported SNP along with metformin plasma 
concentration.  
4.9 Association between metformin plasma level and LKB1 
variations 
As it was reported in the database, LKB1 gene was less variant than the other two 
genes; only four SNPS were reported in all studied populations.  The result of the 
current study showed that the genetic variation of the LKB1 gene was not 
associated with metformin plasma concentrations (p= 0.377) thus LKB1 was not 
included in further regression analysis.   
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Table 21: OCT2 variations with the percentage of the heterozygocity reported in the diabetic 
patients and the percentage of the patients with the polymorphic allele in the higher 
metformin plasma concentration category (above 1.0 mg/L). 
OCT2 variation % Heterozygocity % of polymorphic 
patients with metformin 
level >1.0 mg/L 
p value 
E1 Thr  rs624249 37 15 0.82 
E4 270Ala>Ser   
rs316019 
18 20.5 0.58 
E6 351Leu>Trp 
rs45599131 
<1 0 0.66 
E8 463Arg>Lys 
rs3907239 
2 33 0.24 
E10 Ala       
rs8177521 
7 26 0.21 
 
4.10 Regression model between metformin plasma 
concentration and the associated significant variables  
As previously stated, metformin dose, patient’s GFR, OCT1-E1 synonymous Ser 
SNP (rs1867351), and OCT1-E9 non-synonymous 488Arg>Met SNP 
(rs35270274) were found to be the only factors that were associated with 
metformin plasma concentration in the diabetic patient group. Table 22 
demonstrates the association between each significant variable and metformin 
plasma concentration represented by p value. 
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Table 22: Association between metformin dose (mg/day), GFR (mL/min/1.73m2), OCT1-E1 
Ser synonymous SNP (rs1867351), and OCT1-E9 Arg>Met non-synonymous SNP 
(rs35270274) and metformin plasma concentration (mg/L), n= 273 
Variables p value 
Metformin daily dose (mg/day) 0.012 
GFR (mL/min/1.73m2) 0.001 
OCT1-E1 synonymous Ser SNP (rs1867351) 0.001 
OCT1-E9 non-synonymous  488Arg>Met 
SNP (rs35270274) 
0.001 
 
Furthermore, in order to test the significance of independent significant variables 
with metformin plasma concentration a multiple regression test was applied to 
examine the effect of metformin dose, GFR, OCT1-E1 synonymous Ser SNP 
(rs1867351), and OCT1-E9 non-synonymous 488Arg>Met SNP (rs35270274) on 
metformin plasma concentration. The model was found to be highly significant 
(p< 0.0001), and all of the four variables were found to be significantly associated 
with metformin plasma concentration. Table 23 summarizes the effects of each 
variable on metformin plasma concentration represented by a p value. 
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Table 23: Multiple logistic regression between metformin dose (mg/day), GFR 
(mL/min/1.73m2), OCT1-E1 Ser synonymous SNP (rs1867351), and OCT1-E9 Arg>Met 
non-synonymous SNP (rs35270274) and high metformin plasma concentration as dependent 
variable (mg/L) with odds ratio, 95% CI, and p value, n= 273 
Variable N with high 
metformin level 
Odds ratio 95% CI‡ P 
Metformin dose (mg/day) 
500-< 1900 4 2.19 1.34-3.63 0.002 
1900- < 2500 10 
2500-3000 30 
GFR (mL/min/1.73m2) 
>90 9  
2.08 
 
1.23-3.49 
 
0.06 90-60 26 
<60- >30 9 
30-10 1 
OCT1-E1 synonymous 
Ser SNP (rs1867351) 
Homozygotes 20 2.82 1.30-5.47 0.007 
Heterozygotes 24 
OCT1-E9 non-synonymous 
488Arg>Met SNP (rs35270274) 
Homogygotes 37 6.04 1.66-21.98 0.006 
heterozygotes 7 
‡CI: confidence interval. 
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However, in order to generalize the result to the Arab population, a sub-analysis of 
the data using multiple regression analysis to include only Arab ethnicity (75% of 
the study population). The result confirmed the above observation that metformin 
dose, GFR, OCT1-E1 synonymous Ser SNP (rs1867351), and OCT1-E9 non-
synonymous 488Arg>Met SNP (rs35270274) were predictive factors for 
variability in metformin plasma concentration with p= 0.002, p= 0.035, p= 0.022 
and p= 0.016 respectively (Table 24) 
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Table 24: Multiple logistic regression between metformin dose (mg/day), GFR 
(mL/min/1.73m2), OCT1-E1 Ser synonymous SNP (rs1867351), and OCT1-E9 Arg>Met 
non-synonymous SNP (rs35270274) and metformin plasma concentration (mg/L) odds ratio, 
95% CI  and p value in the Arab ethnic group, n= 219 
Variable N with high 
metformin level  
Odds ratio 95% CI‡ P 
Metformin dose (mg/day) 
500-< 1900 3 2.59 1.42-4.72 0.002 
1900- < 2500 7 
2500-3000 21 
GFR (mL/min/1.73m2) 
>90 7  
1.94 
 
1.05-3.59 
 
0.035 90-60 17 
<60- >30 6 
30-10 1 
OCT1-E1 synonymous  
Ser SNP (rs1867351)  
Homozygotes 14 2.73 1.16-6.45 0.022 
Heterozygotes 17 
OCT1-E9 non-synonymous  
488Arg>Met SNP (rs35270274) 
Homogygotes 26 6.74 1.43-31.6 0.016 
heterozygotes 5 
 
*Research basic data are available upon request.  
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5 Discussion  
According to a recent IDF report (271), diagnosed type 2 DM is highly prevalent 
among both sexes in member states of the Eastern Mediterranean region, and 
highest among member countries of the Gulf Corporation Council including the 
UAE. One of the major health care challenges in the UAE is the lack of national 
data, thus it is difficult to estimate the prevalence of diagnosed diabetes among the 
UAE population. However, based on a national survey conducted jointly by WHO 
and the UAE Ministry of Health between 1998 and 2000 on 2360 UAE nationals 
(272) the overall percentage of type 2 diabetes among UAE citizens was 24%, 
therefore UAE was classified as the second highest country with the highest 
diabetes prevalence within the adult population (20.1%) (271). The prevalence of 
diabetes among the UAE population could be higher than 24% especially with 
increasing levels of obesity (272), changes of lifestyle towards a sedentary pattern 
(272), and with increased prevalence of undiagnosed diabetes (271-272). 
Most type 2 diabetic patients were overweight or obese (273-275).  According to 
available guidelines, Metformin is recommended as first line pharmacological 
therapy in newly diagnosed overweight type 2 diabetic subjects (15-16, 83, 249). It 
is of note that with recent global diabetes management guidelines metformin is 
recommended as the initial pharmacological management option for all patients 
(83, 276). In this study, it was observed that 41% of the diabetic patients had BMI 
values between 30-40 kg/m2 and 78% of the recruited diabetic subjects were 
prescribed antihypertensive medications. These figures reflect community 
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ignorance about diabetes risk factors, endemic of diabetes, and subsequently the 
risk of diabetes complications, and further identifies the need for a prompt 
government decision to initiate national diabetes prevention programs and enhance 
community awareness about this chronic disease. As the antihyperglycemic 
efficacy of metformin does not vary with adiposity to a clinically significant extent 
(277) it is not recommended to adjust metformin dose according to patients BMI. 
This recommendation is supported by the results of this study which observed no 
significant association between metformin plasma concentrations and patients 
BMI.    
Metformin is considered the drug of choice for the treatment of overweight newly 
diagnosed type 2 diabetic patients (15), and it is the most commonly used anti-
diabetic drug. In the USA, metformin accounted for 33% of oral antidiabetic 
prescriptions (278). There has been no national survey regarding the use of 
metformin among diabetic patients in the UAE, however, because of the high 
prevalence of DM among UAE citizens, and low cost of metformin; it could be 
postulated that metformin could be the most common antihyperglycaemic agent 
used in the UAE. Moreover, the result of this study showed that 461 diabetic 
patients were prescribed metformin therapy in four different hospitals and health 
centres in the UAE. It was also observed that out of 292 diabetic subjects, 45 
patients were on metformin mono-therapy while 247 patients were prescribed 
combinations of metformin with other hypoglycaemic agents, which strongly 
indicates that metformin could be the most commonly used oral hypoglycaemic 
agent in the UAE.     
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5.1 Association between metformin plasma concentration and 
demographic and clinical data 
The result of the current study showed that, among all evaluated demographic and 
clinical parameters, metformin dose and GFR were found to be significantly 
associated with metformin plasma concentration (p= 0.002, and p= 0.006 
respectively).  
5.2 Association between metformin plasma concentrations 
and GFR 
Renal disease affects 20-40% of individuals with diabetes (279-281), and diabetic 
nephropathy is the leading cause of end-stage renal disease in developed countries 
(282). The evaluation of renal function is therefore of critical importance in 
diabetic subjects. GFR is the best measure of overall kidney function in health and 
disease (251-252, 283-284). GFR can be directly measured by infusion of external 
substances such as inulin or 51creatinine labeled EDTA (285). However, these 
methods are expensive, not practical and time consuming. The ADA recommends 
estimation of GFR by either Cockroft Gault or MDRD equations in all patients 
with diabetes (286). The MDRD model is recommended for use in Australia for 
the routine estimation of GFR with every request for serum creatinine in adults 
(287).  A body of evidence has suggested that the MDRD formula is more accurate 
and better performing than Cockroft Gault equation in estimating GFR in diabetic 
patients (250-252). It was also reported that MDRD is less influenced by body 
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weight unlike Cockroft Gault equation (288-290). In the current study we have 
used GFR to measure patients kidney function and because the majority of 
subjects were obese (mean BMI 30.36 ±0.35) we estimated GFR using the MDRD 
equation (284) which is less biased in obese patients.  
Pharmacokinetic studies have shown that metformin is rapidly eliminated by the 
kidney by combined glomerular filtration and tubular secretion (104-106). The 
results of this study are in agreement with metformin pharmacokinetic properties, 
as the kidney is the major site of metformin excretion. Therefore, it was not 
surprising to observe that patients with decreased GFR had higher metformin 
plasma concentrations than those with normal kidney function. As a result, one can 
postulate that patients with severe renal impairment might be at higher risk for 
metformin accumulation in the plasma, therefore, subjecting those group of 
patients to unwanted side effects such as gastrointestinal adverse effect and 
possibly lactic acidosis (105-107).  
5.3 Association between patients age, GFR and metformin 
plasma concentration  
Although patient age was not significantly associated with metformin plasma 
concentration, it was significantly associated with patients GFR (p< 0.0001). It is 
known that the most important changes interfering with the pharmacokinetic 
profile of metformin is the progressive decrease of renal function with ageing 
(107, 125-126), thus GFR declines with age. In a study by Sambol et al. (107) they 
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found that both renal function (as measured by Clcr) and age were predictors of 
metformin clearance. In the current study, GFR was a significant predictor of 
metformin plasma level as a single covariate. As mentioned, in this study the 
MDRD equation was used to estimate GFR (253) . Age was included as a function 
in the equation for estimating GFR (253), although patient age was not 
significantly associated with metformin plasma level, thus age should not be 
ignored when prescribing metformin therapy, particularly for elderly patients with 
decreased GFR.    
5.4 Association between patients gender and metformin 
plasma concentration  
This study indicated that there was no significant difference between males and 
females in measured metformin plasma concentrations. This result was in 
agreement with other studies that have observed no gender differences in 
metformin pharmacokinetics (23, 104, 108).   
5.5 Relationship between poor glycemic control and diabetic 
complications  
Poor glycemic control is linked to increased  risk of diabetic complications (15, 
235). In the current study, it was shown that 33% of the patients were diagnosed 
with CVD (MI, angina, and CHF), of which 85% were on combined 
hypoglycaemic therapy. Since this study was not designed to investigate the 
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prevalence of diabetes complications among the recruited subjects, therefore all of 
the medical information was retrieved from patient’s medical record in the diabetic 
clinics only. These medical records barely include other medical conditions such 
as patient cardiovascular or microvascular complications, and the diagnosis of 
diabetic complications were confirmed either by the treating doctors in the diabetic 
clinic or by the patient. Thus, the prevalence of diabetes complications could be 
higher than that observed in this study.  
5.6 Association between metformin plasma concentration and 
metformin dose 
It was shown that metformin dose was significantly associated with metformin 
plasma concentration (p= 0.002). Patients with lower metformin doses had lower 
metformin plasma concentrations and vice versa. This result was consistent with 
other studies, where highly significant association have been reported (105-106, 
113). This observation indicated that prescribing doctors tended to increase 
metformin dose when patients response to metformin was not as desired, and that 
might lead to an addition of another hypoglycaemic agent to metformin therapy. 
The result of this study showed that of 292 diabetic patients only 45 patients were 
on metformin mono-therapy. It was also shown that despite maximizing metformin 
dose and adding other hypoglycaemic agents to metformin therapy, patients had 
poor glycemic control (mean HbA1c=8.15 ±0.12%). This might be due to several 
reasons, including failure to maintain physical activity; because it was observed 
that 51% of the recruited patients led a sedentary lifestyle. Another reason could 
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be non-compliance to drug therapy, 6% of the patients had zero metformin plasma 
concentration despite self reporting of good compliance to the prescribed 
medications. It could also be genetic factors that might affect drug transporters and 
metabolizing enzymes.  
5.7 Association between metformin plasma concentration and 
OCT1, OCT2, and LKB1 genes 
Metformin is well characterized as a substrate of OCT1 and OCT2 drug 
transporters (18-20), and genetic studies have demonstrated that OCT genes 
exhibit polymorphic variation in the coding region (24-27). In vivo and in vitro 
studies have demonstrated the important role played by OCT1 and OCT2 genes in 
the pharmacokinetics, disposition, and efficacy of metformin (21, 32, 223, 233, 
291). In clinical practice it has been shown that patients respond differently to 
metformin treatment (17, 292). Metformin plasma levels are not usually monitored 
in order to determine the effectiveness of  treatment, and they have little clinical 
value except when lactic acidosis is present (103). The variation in metformin 
plasma levels could be used as an indicator of metformin accumulation in the 
plasma, and as a variable that might be associated with other factors which could 
contribute to the inter-individual variation to metformin response.  
Metformin pharmacokinetics have been well characterized in Caucasians (104-
106, 113, 293) and in other populations, such as Chinese (108), Arabs (109), 
Indians (110), African-Americans (293), and Germans (111), no significant 
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difference was observed in metformin pharmacokinetic parameters among those 
populations.   
One of our study aims was to investigate the correlation between the genetic 
variations in OCT1, OCT2, and LKB1 genes and metformin plasma concentration 
in the UAE diabetic population, and to identify the frequency of polymorphisms in 
the drug transporters among diabetic and non-diabetic populations.   
The result of the current study revealed that OCT1, OCT2, and LKB1 genes 
exhibited a polymorphic pattern in the UAE population. It was also observed that 
there was a significant genetic difference in polymorphism in OCT1, and OCT2 
transporters between the UAE population and the Caucasian population.  
A number of studies have compared OCT1 and OCT2 SNPs among various ethnic 
groups, but most of the reports were from Caucasian and Asian populations (26-
29). However, genetic studies are somehow limited in regard to the LKB1 gene. 
5.8 OCT1 genotypes  
In the OCT1 gene, all non-synonymous SNPs have been identified in various 
racial populations with different frequencies (Table16). It was observed that 
although the UAE population as Arab is classified as Caucasian, their observed 
genotype patterns were different than other Caucasians, and surprisingly the allele 
frequencies of some of the reported SNPs were similar to other ethnic groups such 
as Asian and African. For example, the allele frequencies of the non-synonymous 
SNP 160Phen>Leu, and 341Pro>Leu were closer to the reported Japanese and 
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Chinese allele frequencies (267). While the allele frequency of the synonymous 
Ser SNP located in exon 1 (rs1867351) was similar to that reported with Africans. 
This observation was concurrent with Kang et al. (29). Their study evaluated 
genetic polymorphisms of OCT1, and OCT2 genes in Korean subjects while 
investigating the functional properties of the non-synonymous SNPs. They also 
compared the allele frequencies of the major functional SNPs of the OCT1 and 
OCT2 genes in the study population with three other ethnic groups, Vietnamese, 
Chinese, and white Germans (29). An interesting observation was the reported 
OCT1 341Pro>Leu SNP (rs2282143) in the white German population that was not 
detected previously in white European-American population. In addition, they 
found that an OCT2 270Ala>Ser mutation revealed different allele frequencies 
between the white European-American population and white German population 
(15.7%, 2.5%, respectively) (233). They concluded that despite being genetically 
classified as Caucasian, the white German population had a different genetic 
background to the white European- American population, the same result was 
observed in this study when compared between the UAE population and 
Caucasians, the MAF for some of the OCT1 SNPs were different between these 
two populations.  
Interestingly, some of the observed SNPs in the UAE population were found to 
resemble the African population, such as the synonymous Ser SNP identified in 
exon 1 (rs1867351) and in exon 11 (rs16891138). Although the MAF for 
(rs186735) SNP was comparable in both populations, however  it was observed 
that the MAF for the (rs16891138) SNP was lower in the UAE population 
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compared to the African population (1.3% Vs 6% respectively) (267). In this study 
it was found that recruited patients were a blend of different ethnic groups and the 
higher percentage were Arab (Figure 8), with a lower representation of Africans 
(5%). If the multiethnic culture in the UAE population is observed, this may not be 
an unexpected observation. Before oil discovery, the economic life of the UAE 
depended heavily on pearl diving and sea trade in the Gulf and the Indian Ocean 
(294-296). This led to the settlement of different ethnic groups from countries 
along the trade route, such as Iran and India (297). Trade activities with east Africa 
led to the importation of Africans as labourers in the pearling industry in the late 
nineteenth century (298). The African and Iranian ethnic populations have been 
fully integrated as citizens (294-296). It was also observed that among different 
ethnic groups, Africans recorded very high percentage of patients with high 
HbA1c level (93%), moreover, 93% of them were on multi-hypoglycaemic 
therapy, which might indicate poor responds towards the given treatment. One 
factor that might have influenced this result is an increased BMI (>25 kg/m2) 
among African patients. It is known that obesity can lead to poor glycemic control 
(15-16, 299), and it is also known that Africans respond differently to some of the 
drugs such as oral antihypertensive agents compared to white Caucasians (300-
301). This could draw attention to a similar finding with antihyperglycaemic 
agents, especially when some hypoglycaemic agents are metabolized in the liver 
by different enzymes which are subjected to genetic variations among different 
ethnic groups (302-305). The sample size for the African ethnic group was too 
small to confirm this observation in this study.  
129 
 
5.9 OCT2 genotypes  
In comparison with the OCT1 gene, one novel synonymous Ser 279 (A/G) SNP 
was found in exon 1 of the OCT2 gene in three Bedouin (original UAE ethnic) 
subjects belonging to various regions in the northern emirates of the UAE (Figure 
10). Although it is a synonymous SNP, it identifies the unique genetic background 
of this population that was different from other ethnic groups, especially with 
Caucasians. Other than previously mentioned synonymous SNP, all other 
polymorphisms observed in the OCT2 gene have been reported in other 
populations (267). Unlike OCT1, the MAF of some of the SNPs observed in OCT2 
in the UAE population were comparable to the Caucasians, such as synonymous 
SNP in exon 1 (rs624249) and non-synonymous SNP in exon 4 (rs316019) with 
MAF of 44% and 8% in Caucasians compared to 33.4% and 10.3% in the UAE 
population (Table 18). 
5.10 The effect of the cultural and religious factors on the 
genetic make up of the UAE population  
There are recent reports of haplotype-based association studies to increase the 
chance of identifying common disease genes, but the selected haplotype-tag SNPs 
from databases may vary among different ethnic groups (306). Hence, this shows 
that understanding of ethnicity-specific SNP allele frequencies in the UAE 
population has a significant role in choosing which SNPs and genes to investigate 
and to calculate an appropriate sample size for a pharmacogenomics study. The 
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allele frequencies of SNPs particularly non-synonymous SNPs are shown in 
Tables 15 and 17. The high similarity in allele frequencies between the UAE and 
European populations and the presence of certain comparable SNPs with Asians 
and Africans indicated the early migration and settlement of certain ethnic groups. 
This result highlights the importance of critical assessment of allele frequencies 
based on ethnicity. Many of the SNPs reported in the literature and database were 
found to be monomorphic in the UAE population. 
Population substructure will lead to inbreeding-like effects, which can be observed 
by a reduction in the number of observed heterozygotes (Het Obs) when compared 
to the expected number of heterozygotes (Het Exp). The polymorphic SNPs 
observed in the UAE population as a whole and especially the non-synonymous 
SNPs, show a reduction in the Het Obs compared to the Het Exp pooled allele 
frequencies (Table 25). Fis is the amount of inbreeding like effects as measured by 
F- Statistics and data in Table 26 shows the inbreeding-like effect within the UAE 
population (307). Fis indicates the deficiency of average heterozygotes in OCT1 
and OCT2 genes within the entire UAE population and it could be observed that 
almost all significant heterozygote deficits (p< 0.05) may be due to non-random 
mating within the population. Even though Arabs are usually identified as 
Caucasians, modern Arab populations especially in Egypt, Palestine, Jordan and 
Lebanon, are the result of a long history of blending of  different human races 
(308). Although multiple rare mutations may segregate in crossbred population, it 
is noted that founding events followed by population bottle necks may reduce 
allelic diversity, in a way that a single mutation dominates the allelic spectrum in 
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an isolated population (309). Due to cultural and religious practices, most of the 
Arab nations including the UAE still practice consanguineous marriages within 
first cousins and the consanguinity rate maybe as high as 50.5% (310) in the UAE 
population. The major impact of consanguinity is that it increases the inbreeding 
coefficient (311) and the frequency of genetic disorders. Even though this study 
did not take into account the consanguinity factor in the UAE population, the 
presence of largely monomorphic SNPs in the OCT1 and OCT2 genes and the low 
frequency of polymorphic SNPs in comparison with the other populations in the 
database indicates that even though there was a mixture of populations in the semi-
urban areas, still UAE as a whole is an inbred population due to cultural 
influences. The results of the study also indicate that the UAE population is a 
distinct population with some similarities with Caucasians.  
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Table 25: Summary of polymorphisms in OCT1 and OCT2 genes in the UAE population 
with Het Obs, Het Exp, and FIS, n= 462  
Gene Location NCBI SNP ID Het Exp Het Obs Fis  
p value 
OCT1 
 Exon 1 rs1867351 117 106 0.0937 0.1031 
 Exon 2 rs683369 84.45 57 0.3254 < 0.0001 
 Exon 6 rs2282143 29.01 30 -0.0342 1 
 Exon 7 rs628031 35.63 6 0.832 < 0.0001 
 Exon 11 rs16891138 9.88 10 -0.0119 1 
OCT2 
 Exon 1 rs624249 140.77 107 0.2402 < 0.0001 
 Exon 4 rs316019 51.21 27 0.4732 < 0.0001 
 Exon 8 rs8177517 6.96 3 0.5684 < 0.0001 
  Exon 10 rs316003 72.07 41 0.431 < 0.0001 
Het Exp = expected number of heterozygotes, Het Obs = observed number of heterozygotes. 
F-statistics for the UAE population which shows the inbreeding like effect within the UAE 
population (Fis). GENEPOP software was used to estimate the various parameters. p < 0.05 
was considered significant.  
 
5.11 Association between the genetic variations of OCT gene 
and metformin plasma concentration  
 The results of the current study have revealed that among all reported SNPs in the 
UAE population two SNPs were found to be predictive factors for the metformin 
plasma concentrations, OCT1-E1 synonymous Ser SNP (rs1867351), and OCT1-
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E9 non-synonymous 488Arg>Met SNP (rs35270274). This observation was at 
variation with other studies, especially with Shikata et al. (21) who concluded that 
the effect of OCT1 and OCT2 polymorphisms on metformin efficacy may not be 
as significant as expected. The discrepancy in the results could be due to various 
reasons. The most apparent is that each study was conducted in different ethnic 
groups, and as it is known that MAF differ between different populations, common 
alleles in one population are not necessarily common in another population; 
subsequently, the influence of genetic variation on some drug responses will 
significantly differ between different populations (312-313). Arabs are genetically 
classified as Caucasians, however in the current study, it was observed that the 
UAE population exhibited different genotype patterns in OCT1 and OCT2 than 
that reported in Caucasians; accordingly, the UAE population might also respond 
differently to drug therapy than their antecedents. 
Another reason for this discrepancy may be due to different approaches used in 
each study. Shikata et al. (21) used a phenotype-genotype approach to investigate 
the effect of OCT1 and OCT2 variation on metformin efficacy, while our study 
analysed metformin plasma concentrations and investigated the possible 
association between OCT1 and OCT2 genetic variations and the variability in 
metformin plasma levels. The methods used in classifying patients might have 
affected the results and the outcomes in both studies. Shikata et al. classified 
patients into responders and non-responders based on HbA1c level. This 
classification might be vague and confusing, thus patients were not only on 
metformin mono-therapy, some were on sulphonylurea, or insulin combinations. 
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Hence, it is not clear which therapy contributed more to decreasing HbA1c levels. 
Whereas in the current study patients were classified according to metformin 
plasma concentration into normal (below 1.0 mg/L) and high metformin level (≥ 
1.0 mg/L), then the association between metformin plasma level and the genetic 
variation of the candidate genes was examined.  As it can be noticed, this was a 
direct relationship between metformin and other factors affecting its plasma 
concentration including genetic variation of OCT1 and OCT2 genes without 
interference of other agents or factors.  
The result of the current study can be generalized to other Arab populations, as it 
was shown that sub-analysing the data to include only Arab ethnicity revealed the 
same significant association between metformin dose, GFR, promoter linked SNP 
rs1867351 and 488Arg>Met SNP and metformin plasma concentrations (p= 0.002, 
p= 0.035, p= 0.022, and p= 0.016 respectively).     
An interesting finding was the association between metformin plasma 
concentration and a synonymous SNP, OCT1-E1 Ser (rs1867351). There is some 
controversy that all synonymous SNPs are non-functional because they do not 
change the encoded amino acid. In fact, evidence increasingly suggests that gene 
functions and onset of disease could be affected by synonymous polymorphisms 
(314-315). However, there was a suggestion that investigating single synonymous 
SNP might not be the best way to reveal its impact on gene function and drug 
response; instead it has been recommended studying the clinical effects of 
haplotypes rather than single synonymous SNP. Recently, it was found that in one 
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multi-drug resistance gene (MDR1) haplotype, there were two synonymous SNP 
sites that occurred frequently and had a unique contribution pattern in human 
populations (316-317). In vitro and in vivo studies have observed that this MDR1 
haplotype led to several changes, from  mRNA level, protein expression, to 
substrate specificity, and these changes were dependent on the presence of the 
synonymous SNPs (318). The allele frequency of this synonymous SNP varies 
between different ethnic groups thus the haplotype distribution of MDR1 which 
carries this SNP demonstrated a similar pattern (319-323). The presence of 
synonymous polymorphisms in drug transporters that have an impact on gene 
functions is not limited to MDR1 (302), hence, the results of the current study 
strongly suggests the impact of synonymous SNP on transporter function. As it 
was shown in this study OCT1-E1 synonymous Ser SNP (rs1867351) was 
significantly associated with variation in metformin plasma concentration, and 
based on the previous discussion, it was postulated that if this synonymous SNP 
was carried together with other synonymous and/or non-synonymous SNPs in one 
haplotype block, subsequently the affinity of OCT substrate; such as metformin, 
towards drug transporter will decrease. This will lead to decreased hepatic uptake 
and therefore decreased metformin efficacy and increased plasma levels. The 
significance of OCT1-E1 synonymous Ser SNP (rs1867351) on metformin therapy 
was also observed in a recent study by Tzvetkov et al. (22). They observed that 
OCT1 rs1867351 SNP was significantly associated with the renal clearance of 
metformin (p= 0.03). Furthermore, when combined, the effect of promoter-linked 
rs1867351 along with other low-function OCT1 amino acid substitutions 
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Arg61Cys, Ser401Gly, and Met420del, resulted in an increase in the renal 
clearance of metformin concentration by approximately 25%. This observation 
highlights the importance of haplotype linkage analysis for the reported functional 
and non-functional OCT1 and OCT2 SNPs.  
Since this is the first study that has reported polymorphisms in OCT1 and OCT2 
genes in the UAE population, it can be considered as initial data for further linkage 
analysis studies in other Arab populations.  
As it was observed, 19 patients were excluded from further analysis, because they 
recorded zero metformin plasma concentrations. Thus they were considered non-
compliant with metformin therapy. The percentage of non-compliance could be 
higher than what was observed in this study, especially if we consider that there 
could be some patients who were not taking metformin dose as prescribed. 
Therefore, in order to investigate the impact of this masked non-compliance to 
metformin therapy on the observed results, particularly OCT1 genotypes, a 
sensitivity analysis of the data was performed. It was found that even after 
increasing all metformin plasma concentrations by 20%, OCT1-E1 synonymous 
Ser SNP (rs1867351) and OCT1-E9 non-synonymous 488Arg>Met SNP 
(rs35270274) retained their significance with p value of  0.009 and 0.004 
respectively. This indicates the significant and profound impact of the genetic 
polymorphisms of the OCT1 gene on the metformin plasma concentrations.   
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The OCT2 gene was less polymorphic than OCT1, and was not associated with 
metformin plasma concentration. Moreover, one novel synonymous Ser SNP was 
found in the OCT2 gene that has not been previously reported in other populations.  
To our knowledge, no clinical study on diabetic patients has been conducted to 
examine the effect of OCT2 genetic polymorphisms on metformin plasma 
concentration and efficacy. However, a recent study examined the effect of non-
synonymous SNP 279Ser>Ala on the renal elimination of metformin in healthy 
volunteers with European and African-American ancestries (324). In the 
mentioned study, they observed that individuals carrying 270Ser>Ala variant had a 
higher metformin renal clearance compared to those with the reference allele. 
Subsequent linkage analysis for this SNP showed that the 270Ser>Ala SNP in the 
CHB population was linked with four intronic SNPs (rs3912162, rs9346814, 
rs9364551, and rs16891232). These SNPs were not found in the CEU and the YRI 
populations (325). The authors concluded that one of the four intronic SNPs might 
have resulted in changes in OCT2 expression levels in the CHB population, which 
may have led to different observations in different populations. In this current 
study, we observed that 270Ser>Ala was the common non-synonymous SNP 
reported in the UAE population with a MAF of 10.3%. Nevertheless, this SNP was 
not correlated with metformin plasma concentration. One of the reasons for the 
discrepancy between these two observations could be due to different study 
populations (European and African-American vs UAE populations). Moreover, the 
methods used in both studies were varied, in the current study the association 
between the genetic variation of OCT2 and metformin plasma concentration was 
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examined in diabetic patients, in contrast Chen et al. investigated the effect of one 
genetic variant (270Ser>Al) of OCT2 on the renal elimination of metformin in 
healthy, young volunteers. Furthermore, other factors that could contribute to the 
variation in metformin plasma concentration were investigated in this study. GFR 
was significantly associated with the variability in metformin plasma 
concentration. Thus, it was postulated that in the clinical sitting GFR -not OCT2- 
may be the major factor that determine metformin renal elimination in patients 
who are regularly on the therapy. 
 Although OCT2 seems to regulate renal secretion of organic cations through the 
entry step at the basolateral membrane, it does not regulate the exit step at the 
apical membrane of renal tubule cells. Recently, metformin was shown to be a 
good substrate of the multidrug and toxin extrusion (MATE1) transporter (326). 
MATE1 is located in the bile canalicular membrane in the hepatocyte and in the 
brush border of the renal epithelium (327). Thus, MATE1 may contribute to the 
final step of metformin excretion through bile and urine. Hence, it is possible that 
genetic variation in MATE1 also contributes to inter-individual variation in 
metformin plasma concentration, disposition, and efficacy. Both this study and that 
of Chen et al. (23) have not included MATE1 as a possible contributor to 
metformin plasma concentration and its renal elimination. 
As discussed previously, the rate of metformin absorption is slower than its rate of 
elimination, thus intestinal absorption is the rate limiting factor in metformin 
disposition. Recently, metformin was characterized as a substrate of a novel 
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organic cation transporter, plasma membrane monoamine transporter (PMAT) 
(328) which is localized in the human small intestine (328). Thus, PMAT may play 
an important role in metformin absorption; therefore, genetic variations of this 
transporter might contribute to the inter-individual variation in response to 
metformin therapy.  
In summary, the results of the current study may influence the pattern of 
prescribing metformin in clinical practice. It confirmed the important role played 
by genetic factors along with other factors on metformin plasma concentration and 
therefore, its possible efficacy. This finding should augment the rising voices to 
individualize metformin dose for particular patient’s especially elderly and renal 
impaired patients. Thus, in order to avoid unnecessary increments of metformin 
dosage especially when no response is observed, it is recommended to perform a 
genotyping test for the OCT1 gene for this sub-group of patient’s who might be at 
higher risk of adverse effects. It is of note that this recommendation worth 
considering in the available guidelines when prescribing metformin therapy 
especially for elderly and renal impaired patients.   
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6 Conclusion  
This is the first study to genotype OCT1, OCT2, and LKB1 genes in the UAE 
population. It was shown that there was a significant genetic difference in 
polymorphism in OCT1, OCT2, and LKB1 transporters between the UAE and 
Caucasian populations. Furthermore, one novel synonymous Ser 279 (A/G) SNP 
was found in exon 1 of the OCT2 gene. 
It is also the first large study to report a significant association between metformin 
dose, GFR, OCT1-E1 synonymous Ser SNP (rs1867351), and OCT1-E9 non-
synonymous 488Arg>Met SNP (rs35270274) and metformin plasma 
concentrations in the UAE diabetic populations. In addition, it has highlighted the 
importance of synonymous SNPs of OCT genes in drug response and therefore its 
efficacy, which could be generalized in other Arab populations.  
Like the case of genotyping cytochrome P4502C19 with proton pump inhibitors 
therapy (329-330), OCT1 genotyping test could be a useful clinical tool for the 
optimal metformin treatment especially in elderly and renal impaired patients. The 
cost effectiveness of this genotyping test needs to be verified in a future study. 
Since this is the first study that has reported polymorphisms in OCT1, OCT2, and 
LKB1 genes in the UAE population, it can be considered an initial study for 
further pharmacogenomic and linkage analysis studies in other Arab and Middle 
Eastern populations.  
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The results of this study showed reduced representation of mutations affecting the 
function of the OCT family genes in the UAE population; the observation would 
indicate the need to assess genetic polymorphisms in the upstream regulators of 
the OCT pathway, such as AMPK. It is also suggested that the impact of genetic 
polymorphisms in other candidate genes involved in metformin pharmacokinetics 
such as PMAT and MATE that are involved in metformin intestinal absorption and 
renal excretion are evaluated in further studies.  
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7 Limitation  
• Patient physical activity was based on a self report, and it is possible that 
patients were underreporting the actual level of their physical activity it 
could reveal the real reason behind their obesity, the fact that it might 
affect their social images.  
• Patients were not only on metformin mono-therapy, they were on other 
hypoglycaemic agents as well, thus, the impact of other hypoglycaemic 
agents on type 2 diabetes can be a factor. As these would be added after 
metformin, it would be expected metformin had been used at a high 
dosage.   
• Dependence on the diabetic clinic medical files to report patient’s diabetes 
complications. This medical file did not include patients follow up 
examination in other specialized clinics, such as cardiac clinic. Thus, 
complications such as CVD may not have been registered in the diabetic 
clinic records. 
• There are few studies that investigated the relationship between metformin 
levels and factors that might have an impact on it in patients with type 2 
DM. The fact limits the possibility to compare this study results with other 
studies from different settings. 
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• Functional analysis of the novel Ser 279 (A/G) SNP in exon 1 of OCT2 
gene could be a goal of further studies 
• Linkage analysis to describe the haplotype structures of the investigated 
genes could also be considered in further studies. 
• The effect of other genes such as MATE1 and PMAT on metformin 
plasma level could also be an objective for further study. 
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8 Recommendation  
• In order to investigate the association between the genetic polymorphisms 
of OCT1 gene and metformin efficacy in the clinical practice, a 
prospective population study involves diabetic patients on metformin 
therapy only is recommended. Patients could be classified into responders 
and non-responders based on HbA1c levels which should be reported three 
months before initiation of metformin and four months after metformin 
therapy.  
• An association study with large sample size and with the description of the 
haplotype structures of the candidate genes in the UAE population is 
further recommended. 
• In order to examine the role of the novel synonymous Ser 279 (A/G) SNP 
that was observed in the OCT2 gene in the study population, functional 
analysis of this SNP and its haplotype structure in relation with other 
SNPs in the OCT2 gene should be investigated.  
• Pharmacoeconomic studies are required to assess the feasibility of 
applying the results of population pharmacogenomic studies within the 
clinical settings. 
• To individualize metformin therapy in clinical practice, genotyping of 
OCT1, MATE1, and PMAT are required on different populations with 
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different ethnic background. Figure 11 illustrate metformin 
pharmacokinetic pathway and the candidate genes involved in each 
pathway.  
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10 Appendix A 
10.1 Patient information sheet 
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INFORMATION SHEET 
Factors Affecting Metformin Plasma Concentrations 
 
We invite you to participate in a research study of the medication metformin (also known as Diabex, 
Glucophage, Diaformin, Glucomet, Glucohexal).This study is being conducted as part of requirement 
of PHD Degree programme of Sohaila Alawadhi. This study has been approved by the UAE Human 
Ethics Research Committee. If you decide to take part in this research study, it is important that you 
understand the purpose of the study and the procedures you will be asked to undergo. Please read this 
page which will provide you with information about the purpose of the study, potential benefits and 
precaution of the study. 
Nature and the Purpose of the Study 
We have asked you to participate in this study as you are currently using metformin for the treatment 
of diabetes. Metformin is a very effective drug in the treatment of diabetes, and is widely used. The 
manufacturers, however, usually do not recommend its use in patients with very poor kidney function. 
This is because if it is used in such cases, a very rare side effect called lactic acidosis may occur. The 
symptoms of lactic acidosis includes nausea, vomiting, lack of appetite, altered level of consciousness, 
difficulty breathing, abdominal pain and thirsty.However,many patients with only mild kidney 
problems can use this drug safely. Our research is intended to investigate factors that affect metformin 
plasma level and to find out what blood level of metformin is in the circulation of a range of different 
patients with different levels of kidney function. 
Benefits 
We hope that identifying factors that affects metformin plasma level will help prescribing doctors to 
be more confident to adjust metformin doses for particular patients, we also hope that finding out what 
blood level of Metformin is found in patients with different kidney function, that we can determine a 
dose of metformin which will be safe for other patients with the same level of kidney problems. 
What the study will involve 
As part of the study you will have a blood sample taken (10 mL) a procedures that are routinely done 
in the clinic.  Following your consent, a fasting blood sample will be collected before you take any 
metformin and your breakfast for the day. This sample will be analysed for fasting blood glucose, 
HbA1c%, lactate level, metformin concentration, kidney function, and DNA analysis. This procedure 
may be uncomfortable but rarely results in any significant problem.  Side effects that have been noted 
with drawing blood include feeling light-headed or faint, formation of a blood clot, and bruising. You 
will also be asked to give urine sample and saliva for DNA analysis. We will also collect other 
information from your doctor, your self and your medical record about your medical history, kidney 
function and other basic information such as age, height and weight.  
Voluntary Participation and Withdrawal from Study 
Your participation in this study is entirely voluntary. You may withdraw from the study at anytime 
without affecting your normal treatment. 
If you have any complaints or concerns about the way in which the study is being conducted, you may 
contact the chairman of the medical centre or the hospital where your blood samples have been taken  
For any questions on the study please contact: 
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Sohaila Al Awadhi.                                                                     
Pharmacy Department                                                                
Fujairah Hospital,                                                           
Phone: 092242999                                       
E-mail:s.alwadhi@student.curtin.edu.au 
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